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Pax5 Haploinsufficiency Cooperates with BCR-ABL1 to Induce Acute
Lymphoblastic Leukemia
Abstract
Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy and comprises several
distinct subtypes each with its own unique pathogenesis, clinical behavior, and response to therapy.
Chromosomal aberrations are a hallmark of ALL but alone fail to induce leukemia. Pediatric ALLs can be
divided into several categories based on the expression of several genetically conserved chromosomal
translocations including the t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1],
MLLrearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage leukemia. Each
translocation confers a characteristic transforming phenotype within the cell in which it originates but is
alone insufficient to induce overt leukemia. In order to identify oncogenic lesions that cooperate with the
aforementioned initiator lesions, we have performed genome-wide analysis of leukemia cells from 242
pediatric ALL patients using high resolution, single-nucleotide polymorphism microarrays. Our analysis
revealed deletion, amplification, point mutation, and structural rearrangements in genes encoding
principal regulators of B lymphocyte development and differentiation in 40% of B-progenitor ALL cases.
The PAX5 gene was the most frequent target of somatic mutation, being altered in 31.7% of cases. The
identified PAX5 mutations resulted in reduced levels of PAX5 protein or the generation of hypomorphic
alleles. Deletions were also detected in TCF3 (also known as E2A), EBF1, LEF1, IKZF1 (IKAROS), and
IKZF3(AIOLOS). These findings suggest that direct disruption of pathways controlling B-cell development
and differentiation contributes to B-progenitor ALL pathogenesis. Moreover, these data demonstrate the
power of high-resolution, genome-wide approaches to identify new molecular lesions in cancer.
The Philadelphia chromosome, a chromosomal abnormality that encodes BCR-ABL1, is the defining
lesion of chronic myelogenous leukemia (CML) and a subset of ALL. To specifically define oncogenic
lesions that cooperate with BCR-ABL1 to induce ALL, we subsequently performed genome-wide analysis
of diagnostic leukemia samples from 304 individuals with ALL, including 43 BCR-ABL1 B-progenitor ALLs
and 23 CMLcases. IKZF1 (encoding the transcription factor Ikaros) was deleted in 83.7% of BCR-ABL1
ALL, but not chronic-phase CML. Deletion of IKZF1 was also identified as an acquired lesion at the time of
transformation of CML to ALL (lymphoid blast crisis). The IKZF1 deletions resulted in haploinsufficiency,
expression of a dominant-negative Ikaros isoform, or the complete loss of Ikaros expression. Sequencing
of IKZF1deletion breakpoints suggested that aberrant RAG-mediated recombination is responsible for the
deletions. These findings suggest that genetic lesions resulting in the loss of Ikaros function are an
important event in the development of BCR-ABL1 ALL.
In order to assess the contribution of the loss of B-cell developmental regulatory genes with BCR-ABL1
we performed bone marrow transplant assays. Pax5haploinsufficiency was shown to cooperate with BCRABL1 during leukemogenesis. Furthermore, as seen in human ALL, both Pax5 and p19Arf
haploinsufficiency further cooperate during leukemogenesis. Pathological analysis of the leukemias
revealed a B-lymphoid phenotype suggesting that this model results in the development of ALL.
Secondary transplant studies confirmed that this was ALL and not a lymphoproliferative disorder.
Immunophenotypic analysis confirmed the B-ALL phenotype and further revealed striking differences
between Pax5+/+, Pax5+/-, and Pax5-/- leukemias. The leukemias that have lost either one or both Pax5
alleles revealed a more immature immunophenotype that was most pronounced in those with bi-allelic
Pax5 loss. The wild-type leukemias were consistent with a Hardy fraction C immunophenotype while the
Pax5 null leukemias were akin to Hardy fraction A with no expression of any definitive B-cell surface
antigens except B220 and CD43.
The Pax5+/+ and Pax5+/- leukemias were monoclonal while the Arf+/- and the compound heterozygous

(Pax5+/- Arf+/-) leukemias were oligoclonal suggesting that the loss of p19Arf confers greater
leukemogenic properties to a cell than does Pax5 loss. This is substantiated by the data that Arf
heterozygous animals are tumor prone alone while Pax5 heterozygous animals live full normal lives.
Genomic analysis of 50 murine leukemias (15 WT, 25 Pax5+/- and 10 Arf+/-) revealed that some of the
same genomic abnormalities found in human ALL also develop in our murine ALL model. This finding
suggests that our model is accurately recapitulating the development of human ALL. Furthermore, we
have found through extensive gene expression studies that our mouse BCR-ABL1 leukemias share a gene
expression profile similar to human BCR-ABL1 leukemias further supporting our murine model of ALL.
The gene expression studies that we have performed have also given us insight into the role that Pax5
haploinsufficiency may be playing during leukemogenesis. Recently D.J Wong et al performed an
exhaustive study of embryonic and adult stem cell gene expression profiling. He found that there are
modules of genes that are common to either embryonic or adult stem cells. He went further to delineate a
group of genes that are commonly expressed in both murine and human embryonic stem cells and call
this the core ESC-like module. We performed gene set enrichment analysis (GSEA) using this core ESClike module and found that this geneset is significantly enriched in our murine leukemias. In addition, we
found that this core ESC-like module was significantly enriched in normal Hardy fraction B cells, but not in
A, or C-F. We also found, using a principal component analysis method, that Pax5+/+ leukemias are most
similar to Hardy fraction C while leukemias that have lost either one or both Pax5 alleles are most similar
to Hardy fraction B suggesting that the loss of Pax5 blocks B-cell development and results in cells that
are more similar to a stage that shares similar expression of embryonic stem cell genes. Taken together
this data suggests that by losing Pax5 the leukemia becomes more stem cell like and may gain
advantages that other B-cells do not because they continue down the road of differentiation.
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“But seek first His kingdom and His righteousness,
and all these things will be added to you.”
Matthew 6:33
“Call to Me and I will answer you,
and I will tell you great and mighty things, which you do not know.”
Jeremiah 33:3
“The secret of my success? It is simple. It is found in the Bible.”
George Washington Carver
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ABSTRACT
Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy and
comprises several distinct subtypes each with its own unique pathogenesis, clinical
behavior, and response to therapy. Chromosomal aberrations are a hallmark of ALL but
alone fail to induce leukemia. Pediatric ALLs can be divided into several categories
based on the expression of several genetically conserved chromosomal translocations
including the t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], MLL
rearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage
leukemia. Each translocation confers a characteristic transforming phenotype within the
cell in which it originates but is alone insufficient to induce overt leukemia. In order to
identify oncogenic lesions that cooperate with the aforementioned initiator lesions, we
have performed genome-wide analysis of leukemia cells from 242 pediatric ALL patients
using high resolution, single-nucleotide polymorphism microarrays. Our analysis
revealed deletion, amplification, point mutation, and structural rearrangements in genes
encoding principal regulators of B lymphocyte development and differentiation in 40% of
B-progenitor ALL cases. The PAX5 gene was the most frequent target of somatic
mutation, being altered in 31.7% of cases. The identified PAX5 mutations resulted in
reduced levels of PAX5 protein or the generation of hypomorphic alleles. Deletions were
also detected in TCF3 (also known as E2A), EBF1, LEF1, IKZF1 (IKAROS), and IKZF3
(AIOLOS). These findings suggest that direct disruption of pathways controlling B-cell
development and differentiation contributes to B-progenitor ALL pathogenesis.
Moreover, these data demonstrate the power of high-resolution, genome-wide approaches
to identify new molecular lesions in cancer.
The Philadelphia chromosome, a chromosomal abnormality that encodes BCRABL1, is the defining lesion of chronic myelogenous leukemia (CML) and a subset of
ALL. To specifically define oncogenic lesions that cooperate with BCR-ABL1 to induce
ALL, we subsequently performed genome-wide analysis of diagnostic leukemia samples
from 304 individuals with ALL, including 43 BCR-ABL1 B-progenitor ALLs and 23
CMLcases. IKZF1 (encoding the transcription factor Ikaros) was deleted in 83.7% of
BCR-ABL1 ALL, but not chronic-phase CML. Deletion of IKZF1 was also identified as
an acquired lesion at the time of transformation of CML to ALL (lymphoid blast crisis).
The IKZF1 deletions resulted in haploinsufficiency, expression of a dominant-negative
Ikaros isoform, or the complete loss of Ikaros expression. Sequencing of IKZF1 deletion
breakpoints suggested that aberrant RAG-mediated recombination is responsible for the
deletions. These findings suggest that genetic lesions resulting in the loss of Ikaros
function are an important event in the development of BCR-ABL1 ALL.
In order to assess the contribution of the loss of B-cell developmental regulatory
genes with BCR-ABL1 we performed bone marrow transplant assays. Pax5
haploinsufficiency was shown to cooperate with BCR-ABL1 during leukemogenesis.
Furthermore, as seen in human ALL, both Pax5 and p19Arf haploinsufficiency further
cooperate during leukemogenesis. Pathological analysis of the leukemias revealed a Blymphoid phenotype suggesting that this model results in the development of ALL.
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Secondary transplant studies confirmed that this was ALL and not a lymphoproliferative
disorder. Immunophenotypic analysis confirmed the B-ALL phenotype and further
revealed striking differences between Pax5+/+, Pax5+/-, and Pax5-/- leukemias. The
leukemias that have lost either one or both Pax5 alleles revealed a more immature
immunophenotype that was most pronounced in those with bi-allelic Pax5 loss. The
wild-type leukemias were consistent with a Hardy fraction C immunophenotype while
the Pax5 null leukemias were akin to Hardy fraction A with no expression of any
definitive B-cell surface antigens except B220 and CD43.
The Pax5+/+ and Pax5+/- leukemias were monoclonal while the Arf+/- and the
compound heterozygous (Pax5+/- Arf+/-) leukemias were oligoclonal suggesting that the
loss of p19Arf confers greater leukemogenic properties to a cell than does Pax5 loss. This
is substantiated by the data that Arf heterozygous animals are tumor prone alone while
Pax5 heterozygous animals live full normal lives.
Genomic analysis of 50 murine leukemias (15 WT, 25 Pax5+/- and 10 Arf+/-)
revealed that some of the same genomic abnormalities found in human ALL also develop
in our murine ALL model. This finding suggests that our model is accurately
recapitulating the development of human ALL. Furthermore, we have found through
extensive gene expression studies that our mouse BCR-ABL1 leukemias share a gene
expression profile similar to human BCR-ABL1 leukemias further supporting our murine
model of ALL.
The gene expression studies that we have performed have also given us insight
into the role that Pax5 haploinsufficiency may be playing during leukemogenesis.
Recently D.J Wong et al performed an exhaustive study of embryonic and adult stem cell
gene expression profiling. He found that there are modules of genes that are common to
either embryonic or adult stem cells. He went further to delineate a group of genes that
are commonly expressed in both murine and human embryonic stem cells and call this
the core ESC-like module. We performed gene set enrichment analysis (GSEA) using
this core ESC-like module and found that this geneset is significantly enriched in our
murine leukemias. In addition, we found that this core ESC-like module was
significantly enriched in normal Hardy fraction B cells, but not in A, or C-F. We also
found, using a principal component analysis method, that Pax5+/+ leukemias are most
similar to Hardy fraction C while leukemias that have lost either one or both Pax5 alleles
are most similar to Hardy fraction B suggesting that the loss of Pax5 blocks B-cell
development and results in cells that are more similar to a stage that shares similar
expression of embryonic stem cell genes. Taken together this data suggests that by losing
Pax5 the leukemia becomes more stem cell like and may gain advantages that other Bcells do not because they continue down the road of differentiation.
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CHAPTER 1
GENERAL INTRDUCTION
Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy
accounting for 75% to 85% of all leukemia’s1 and occurs in roughly 31 per million
children under the age of 15 each year.2-4 In contrast, adult ALL comprises 15% of
leukemia’s with an annual incidence estimated at 22 per million in individual’s ≥25 years
old (www.seer.cancer.gov). ALL is distinguished from lymphoblastic lymphoma by the
presence of ≥25% lymphoid blasts in the bone marrow. Currently, the World Health
Organization (WHO) uses an integrated morphologic, immunologic, and cytogenetic
disease classification system. The WHO also incorporates current knowledge of
molecular lesions associated with different subtypes to help properly classify and risk
stratify ALLs.5 According to the WHO classification system, ALLs can be divided in to
several genetically distinct subtypes including B-progenitor leukemia’s with the
translocations t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], MLL
rearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage leukemia
(Figure 1-1). These genetic lesions have been shown to be important in leukemia
initiation6 but cooperating oncogenic lesions are required for leukemia development.
In an effort to identify cooperating oncogenic lesions, our laboratory has recently
performed a genome-wide analysis of pediatric ALL using single nucleotide
polymorphism microarrays (SNP).7 The SNP arrays allow us to investigate copy number,
that is, the number of alleles that a leukemia has at a given genomic locus. The SNP
arrays also reveal information about genotype and copy number loss of heterozygosity
(LOH). LOH is a phenomenon that occurs when one allele undergoes gene conversion
into another allele. For example, if a leukemia had the following genotype at the PAX5
locus AB; then one allele is A and the other is B. When the leukemia develops, the SNP
data may reveal that the leukemia shows a genotype of AA or BB at the PAX5 locus and,
as a result, one can conclude that LOH has occurred at this locus. Chapter 2 of this
dissertation will outline the results of the SNP analysis. Briefly, the SNP analysis
identified mutations in genes encoding regulators of B-cell development and
differentiation in 40% of B-progenitor ALL cases. Of these genetic lesions, deletion of
the transcription factor PAX5 was the most common mutation occurring in 32% of cases.
The result of the PAX5 mutations was a reduction in the level of the transcription factor
as a result of gene deletion/point mutation or generation of an altered form of PAX5
protein.
Pax5, which is also known as B-cell specific activator protein (BSAP), is a
transcription factor that is only expressed in the B lymphoid lineage of the hematopoietic
system.8 Pax5 is a major regulator of B-cell development controlling the expression of
many B-cell specific genes including Cd19, Blnk, Lef1, Ebf1, Cd79a, and Mb1.9-14 Pax5
also controls the expression of alternate lineage genes such as Flt3, Notch1, Lmo2, and
Cd28 by down regulating their expression.15 The expression of Pax5 is so important for
proper B-cell development that loss of Pax5 results in an arrest in B-cell development at
an early B-cell progenitor stage in Pax5-/- mice.16 Interestingly, Pax5 is so important for
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Figure 1-1 Subtypes of pediatric acute leukemia
Acute leukemia can be sub-divided into B-lineage and T-lineage leukemia’s based on cell
surface antigen immunophenotyping. B-lineage leukemia’s are more common than Tlineage in children and can be subdivided into groups based on chromosomal
abnormalities such as whole chromosome deletion, amplification, and chromosomal
translocations. These chromosomal abnormalities often have prognostic significance i.e.
BCR-ABL and MLL rearranged leukemia’s carry a poor prognosis while hyperdiploid and
TEL-AML1 leukemia’s are associated with better outcomes. Adapted with permission.
Pui, C, Relling, M, and Downing J. Acute lymphoblastic leukemia. New England Journal
of Medicine 350, 1535-1548 (2004).17
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B-cell fate determination that B-cells from Pax5-/- mice can dedifferentiate into alternate
lineages.18 Chapter 2 of this dissertation will discuss the effects that Pax5 deletions and
mutations have on the ability of Pax5 to transactivate the known Pax5 targets Cd19 and
Cd79a.
The genome-wide SNP study that we performed revealed that regulators of B-cell
development are deleted in 40% of ALLs with PAX5 being the most common target of
mutation at 32% of cases. The frequency and type of mutations varied by leukemia
subtype, specifically, PAX5 was deleted in 13/47 (28%) ETV6-RUNX1, 7/17 (41%)
TCF3-PBX1, and 4/9 (44%) BCR-ABL1 ALL cases.7 Because the number of BCR-ABL1
cases analyzed in the study was small, we subsequently analyzed 43 BCR-ABL1 ALLs
including 21 pediatric and 22 adult cases19 (chapter 4). The, now more robust, analysis
revealed that 22/43 (51%) of BCR-ABL1 ALL cases harbored mutations in the PAX5
gene. Specifically, 12/21 (57%) of pediatric ALL and 10/22 (45%) of adult ALL cases
harbored copy numbers abnormalities (CNA) at the PAX5 locus. The PAX5 mutations
resulted in the functional loss of one PAX5 allele, suggesting that PAX5
haploinsufficiency may cooperate with BCR-ABL1 to induce ALL.
The BCR-ABL1 fusion, also known as, the Philadelphia chromosome (Ph), is the
pathognomonic lesion in chronic myelogenous leukemia (CML).20 Ph positive leukemia
also accounts for 5% of B-progenitor pediatric ALL and 40% of adult ALL, in addition to
CML.21,22 The BCR-ABL1 fusion arises from the t(9,22)(q34;q11.2) translocation which
leads to the fusion of the ABL proto-oncogene from chromosome 9 with the breakpoint
cluster region (BCR) gene on chromosome 22.23,24 The generation of the Ph chromosome
can lead to the formation of alternative products depending on the context of the
leukemia. The p210BCR-ABL1 and the p185BCR-ABL1 fusion proteins are typically found in
CML and Ph+ ALL, respectively.25-27 The BCR-ABL1 protein encodes a constitutively
active tyrosine kinase that is important for cell transformation.26,28 The Ph chromosome
has also been shown to be an important negative prognostic indicator in both pediatric
and adult ALL.29-31
Chapter 3 will describe the generation of a p185BCR-ABL1 mouse model of ALL
which will also incorporate the additional lesions that we have detected using the SNP
analysis. Specifically, both Pax5 and p19Arf haploinsufficiency will be modeled on the
BCR-ABL1 background individually and together in order to assess their ability to
cooperate with the Ph chromosome to induce ALL. This model will be analyzed for
additional cooperating events, as well as, assessed for its similarity to human Ph+ ALL
using gene set enrichment analysis (GSEA). The GSEA analysis will bring this
dissertation full circle; from the identification of lesions in human ALL to mouse
modeling of those lesions and the comparison of the effects that these lesions have on
transcriptional networks in humans and in mice. This analysis will allow us to better
understand the human disease and will help us to move closer to developing therapeutics
that will eventually cure children with ALL.
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CHAPTER 2
GENOME-WIDE ANALYSIS OF GENETIC ALTERATIONS IN ACUTE
LYMPHOBLASTIC LEUKEMIA
2.1 INTRODUCTION
Pediatric acute lymphoblastic leukaemia (ALL) consists of genetically distinct
subtypes including B-progenitor leukaemia’s with t(9;22)[BCR-ABL1], t(1;19)[TCF3PBX1], t(12;21)[ETV6-RUNX1], rearrangements of MLL, hyper- and hypodiploid
karyotypes, and T-lineage leukaemia (T-ALL). These genetic lesions are important in
leukemia initiation,6 but alone are insufficient to generate a full leukemic phenotype,
suggesting that cooperating oncogenic lesions are required. Although additional
mutations have been identified in a subset of cases, the full complement of cooperating
lesions and their distribution within the known genetic subtypes of ALL remains to be
defined.
To obtain a comprehensive registry of genetic lesions in ALL, we examined DNA
from the leukemic blasts of 242 cases of pediatric ALL using Affymetrix SNP arrays that
interrogate over 350,000 loci and permit identification of copy number changes at an
average resolution of less than 5kb. In addition, paired copy number and LOH analysis
was performed for 228 ALL cases with matched remission samples. Our analyses
identified a mean of 6.46 somatic copy number alterations per case, with deletions
outnumbering amplification almost 2:1 (Table 2-1). The frequency of genomic deletions
and amplifications varied significantly between ALL subtypes (Table 2-1). Genomic
gains were frequent in B-progenitor ALL with high hyperdiploidy, but were rare in other
B-ALL subtypes. By contrast, deletions were more frequent, ranging from 6 deletions per
case in some genetic subtypes (ETV6-RUNX1 and hypodiploid ALL) to only a single
deletion per case in MLL-rearranged ALL.
Fifty-four recurrent somatic regions of deletion were identified, with the minimal
deleted regions typically measuring less than 1 Mb in size, and 24 of the deletions
containing only a single gene. None were present in the germline samples. Although
technical aspects of the methodology used could theoretically lead to false positive or
negative results, FISH and/or qPCR confirmatory studies described below validated each
of the examined lesions. The recurring deletions included 3p14.2 (FHIT),32 6q16.2-3
(including CCNC),33 9p21.3 (two regions involving CDKN2A34 and MLLT3), 12p13.2
(ETV6),35 11q23 (including ATM),36 13q14.2 (RB1)37 and 13q14.2-3 (including mir-16-1
and mir-15a).38 In addition, deletions of other tumor associated genes not previously
implicated in ALL were identified including LEF1, BTG1, and ERG. The most striking



Adapted with permission. Mullighan C, Goorha S, Radtke I, Miller C, Coustan-Smith E, Dalton J,
Girtman K, Mathew S, Ma J, Pounds S, Su X, Pui C, Relling M, Evans W, Shurtleff S, Downing J.
Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 446, 758-764
(2007).7
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Table 2-1 Frequency of genomic amplification and deletions in pediatric ALL
Group

N
39
17
47
11
9
23
10
36
192

Amplifications
mean ± SD (range)
9.56 ± 3.59 (5-20)
1.59 ± 0.62 (1-3)
0.89 ± 1.51 (0-8)
0.09 ± 0.3 (0-1)
4 ± 5.3 (0-12)
1.70 ± 1.55 (0-7)
1.1 ± 1.91 (0-6)
1.06 ± 3.21 (0-19)
2.97 ± 4.28 (0-20)

Deletions
mean ± SD (range)
1.59 ± 2.49 (0-11)
2.12 ± 1.17 (1-4)
6.0 ± 4.63 (1-21)
0.91 ± 1.81 (0-6)
4.2 ± 4.15 (0-12)
3.5 ± 3.12 (0-12)
6.0 ± 4.42 (3-18)
4.64 ± 5.14 (0-20)
3.83 ± 4.2 (0-21)

All lesions
mean ± SD (range)
11.13 ± 5.0 (5-27)
3.7 ± 1.53 (2-7)
6.68 ± 4.8 (0-21)
1 ± 1.79 (0-6)
6.8 ± 4.52 (0-13)
5.1 ± 4.31 (0-15)
7.1 ± 6.12 (3-24)
5.58 ± 6.57 (0-23)
6.63 ± 5.56 (0-27)

T-ALL

50

0.9 ± 1.98 (0-9)

4.9 ± 6.21 (0-30)

5.8 ± 7.12 (0-39)

All cases

242

2.54 ± 4.0 (0-20)

4.06 ± 4.69 (0-38)

6.46 ± 5.90 (0-39)

B-ALL

Subtype
Hyperdiploidy with >50 chromosomes
TCF3-PBX1
ETV6-RUNX1
MLL rearranged
BCR-ABL1
Hyperdiploidy with 47-50 chromosomes
Hypodiploid
Other
Total

Lesions exclude inherited copy number variations,39 as well as focal deletions arising from antigen receptor gene rearrangements at
2p11.2 (IGKL), 7p14.1 (TRGV), 7q34 (TRBV), 14q11.2 (TRAV, TRDV, TRDJ, TRDC, and TRAJ), 14q32.33 (IGHV) and 22q11.22
(IGLL). Homozygous deletions are scored as two lesions. There is significant variation in the mean number of amplifications
(ANOVA P<0.0001), deletions (P<0.0001), and all lesions (P<0.0001) between B-progenitor ALL subtypes. Amplifications are more
common in B-ALL than T-ALL (t test P=0.001).
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observation, however, was the identification of genomic alterations in genes that regulate
B-lymphocyte differentiation in 40% of B-progenitor ALL cases.
2.2 MATERIALS AND METHODS
2.2.1 Patients and Samples
Two hundred and forty two patients with acute lymphoblastic leukemia (ALL)
treated at St Jude Children’s Research Hospital (SJCRH) between 1993 and 2005 were
studied. These included precursor-B ALL with high hyperdiploidy (greater than 50
chromosomes on karyotyping, HD>50, n=39), TCF3-PBX1 positive (E2A-PBX1, n=17),
ETV6-RUNX1 positive (TEL-AML1, n=47), BCR-ABL1 positive (n=9), MLL rearranged
(n=11), low hyperdiploidy (47-50 chromosomes, HD47-50, n=23), hypodiploidy (n=10),
B-ALL with pseudodiploidy, near haploid karyotype, normal cytogenetics or nonrecurring cytogenetic abnormalities (n=36), and T-lineage ALL (T-ALL, n=50).
Informed consent for the use of leukemic cells for research was obtained from
patients, parents or guardians in accordance with the Declaration of Helsinki, and study
approval was obtained from the SJCRH institutional review board.
Mononuclear cells were purified from the diagnostic bone marrow or peripheral
blood samples by density gradient centrifugation and were cryopreserved in liquid
nitrogen. Diagnostic samples were characterized by conventional cytogenetics, reverse
transcriptase–polymerase chain reaction (RT-PCR) assays for BCR-ABL1, TCF3-PBX1
[E2A-PBX1], and ETV6-RUNX1 [TEL-AML1], and for the presence of MLL chimeric
fusion genes by at least two of the following methods: cytogenetics, 11q23 fluorescence
in situ hybridization (FISH), or RT-PCR for t(9;11)[MLL-AF9], t(11;19)[MLL-ENL],
t(11;19)[MLL-ELL], t(10;11)[MLL-AF10], or t(4;11)[MLL-AF4]. Remission samples
were obtained from peripheral blood collected into EDTA vacutainer tubes at a median
time of 200 days (range <1-3009) from diagnosis.
DNA was extracted from diagnostic leukemia samples using the DNA Blood
Mini Kit (Qiagen, Valencia, CA). DNA was quantified using either a Nanodrop
Spectrophotometer or PicoGreen. Quality was assessed using the Nanodrop and by
agarose gel electrophoresis. RNA was extracted from diagnostic samples using TRIzol
(Invitrogen, Carlsbad, CA). Cells for FISH analysis were stored in Carnoy’s fixative.
2.2.2 Affymetrix Mapping 100K and 500K Single Nucleotide Polymorphism Arrays
Samples were genotyped with Affymetrix 50K GeneChip Human Mapping 50K
Hind, 50K Xba, and 250K Sty arrays (Affymetrix, Santa Clara, CA). DNA was
restriction enzyme digested, PCR-amplified, purified, labeled, fragmented and hybridized
to the arrays according to the manufacturer’s instructions. Briefly, 250ng of DNA was
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digested with XbaI, HindIII or StyI (New England Biolabs, Boston, MA). Digested DNA
was adaptor-ligated and PCR-amplified using AmpliTaq Gold (Applied Biosystems,
Foster City, CA) in four 100l PCR reactions for each enzyme-digested sample. PCR
products from each set of four reactions were pooled, concentrated and fragmented using
DNase I. Fragmented PCR products were then labeled, denatured and hybridized to the
arrays. Arrays were then washed using Affymetrix fluidics stations, and scanned using
the Gene Chip Scanner 3000. CEL files were generated using either Affymetrix
GeneChip Operating Software v 3.0 or Affymetrix GeneChip Genotyping Analysis
Software (GTYPE) v 4.0. SNP calls were generated using GTYPE. Affymetrix CEL and
GTYPE-generated SNP call text files for the 242 blast samples, corresponding remission
samples in those cases with PAX5 or EBF1 mutations, and the 62 remission samples used
as diploid reference samples for copy number analysis have been deposited in NCBIs
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible
through GEO Series accession number GSE5511.
2.2.3 Fluorescence In Situ Hybridization (FISH) Analysis
Dual-color FISH was performed on archived bone marrow cells obtained at
presentation, treated with Carnoy’s fixative and dried onto slides. Probes were derived
from bacterial artificial chromosome (BAC) clones (Children’s Hospital Oakland
Research Institute, Oakland, CA.; Invitrogen; Open Biosystems, Huntsville, AL). BACs
used were RP11-586B19 (EBF1 deletion), RP11-160B5 (EBF1 deletion, case HypodipSNP-#5), RP11-96F2 (PAX5 deletion), CTD-2535J16 (PAX5 deletion), RP11-614P24
and RP11-1136K1 (PAX5-ETV6 fusion), RP11-652D9 and RP11-79P21 (PAX5-FOXP1
fusion), RP11-652D9 and RP11-73L12 (PAX5-ZNF521 fusion) RP11-652D9 (PAX5
amplification in case Hypodip-SNP-#7), CTC-600N23 (IKZF3 deletion). BACs labeled
for control probes were CTD-2194L12 (5p13.2), RP11-235C23 (9q31.2) and RP11-4F24
(17p13.3).
BAC clone identity was verified by T7 and SP6 BAC-end sequencing and by
hybridization of fluorescently labeled BAC DNA with normal human metaphase
preparations. BACs were labeled with either fluorescein isothiocyante or rhodamine
fluorochromes. Target probes were paired with control probes from the opposite
chromosomal arm where possible. All probe mixtures were diluted 1:50 in DenHyb
buffer (Insitus Biotechnologies, Albuquerque, NM) and co-denatured with the target cells
on a hotplate at 90°C for 1 minute. The slides were incubated overnight at 37°C on a
slide moat and then washed in 50% formamide/1xSSC at 25°C for 5 minutes. Nuclei and
metaphases were counterstained with DAPI (200ng/ml) (Insitus Bio.) for viewing on
either an Olympus BX60 or a Nikon Eclipse E800 fluorescence microscope equipped
with a 100 watt mercury lamp; FITC, Rhodamine, and DAPI filters; a 100X PlanApo
(1.40) oil objective; and a COHU CCD or Photometrics SenSys camera. Images were
captured and processed with an exposure time ranging from 0.5-2 seconds for each
fluorochrome using Cytovision v3.6 software from Applied Imaging (San Jose, CA).
Images were captured and enhanced using Applied Imaging’s MacProbe v4.3 software.
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2.2.4 Fluorescence Activated Cell Sorting
Sorting of leukemic blasts according to level of CD10 expression was performed
using a BD FACSAria Cell-Sorting System and a phycoerythrin-labeled anti-CD10
antibody (BD Pharmingen, BD, Franklin Lakes, NJ).
2.2.5 Genomic Sequencing
All 16 exons of EBF1 were sequenced using genomic DNA from 8 blast samples
with EBF1 deletions and an additional 106 B-progenitor ALL cases without EBF1
deletions. DNA was amplified using Accuprime Pfx DNA polymerase (Invitrogen) or
Accuprime GC-rich DNA polymerase (Invitrogen). Exon sequences were determined
aligning the reference EBF1 mRNA and DNA sequences (Genbank accessions
NM_024007.2 and NC_000005.8). The coding regions of all 11 exons of PAX5 (exons
1A, 1B, and 2-10) and the promoter region of exon 1B were sequenced in all 242 blast
samples. Remission samples for patients with blast samples harboring PAX5 mutations
were also sequenced. Primers were designed using Primer 3.40 PCR amplification was
performed according to the manufacturer’s instructions using Eppendorf Mastercyclers
(Eppendorf North America, Westbury, NY). Thermal cycling parameters for Accuprime
Pfx DNA polymerase were 95°C for 2 minutes followed by 35 cycles of 95°C for 15
seconds, 60°C for 30 seconds, and 68°C for 60 seconds. Thermal cycling parameters for
Accuprime GC-rich DNA polymerase were 95°C for 3 minutes followed by 35 cycles of
95°C for 30 seconds, 60°C (or annealing temperature as indicated in Supplementary
Tables 3-5) for 30 seconds, and 72°C for 60 seconds, with a final extension of 10 minutes
at 72°C. PCR products were purified using the Wizard SV Gel and PCR Clean-Up
System (Promega, Madison, WI). PCR products were sequenced directly using Big Dye
Terminator (v.3.1) chemistry on 3730xl DNA Analyzers (Applied Biosystems, Foster
City, CA). Mutations detected by direct sequencing were confirmed by cloning PCR
products into either pCR2.1-TOPO (Invitrogen) or pGEM-T Easy (Promega, Madison,
WI) vectors, and sequencing multiple clones in both directions using M13 primers.
2.2.6 Modeling of PAX5 Paired Domain Mutations
A structural view of the PAX5 paired domain was generated by PyMOL v0.99
(http://pymol.sourceforge.net/) using the coordinates of the X-ray structure of PAX5
interacting with ETS1 on DNA, and PAX6 deposited with the Brookhaven Data Bank
(PDB: 1K78 and 6pax; http://www.rcsb.org/pdb/).41,42 The protein sequences of the
paired domains of PAX6 and PAX5 are 70.1% identical.
2.2.7 Cell Culture
The human pre-B ALL cell lines Kasumi-2 and REH, the Burkitt lymphoma cell
line Raji, and the T-lineage ALL cell lines Jurkat and MOLT-4 (all obtained from the
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Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, Braunschweig,
Germany) were grown in RPMI-1640 containing 100 units/ml penicillin, 100 µg/ml
streptomycin, 2 mM glutamine and 10% fetal bovine serum (20% for MOLT-4). 293T
cells were maintained in DMEM containing 100 units/ml penicillin, 100 µg/ml
streptomycin, 2 mM glutamine and 10% fetal bovine serum.
2.2.8 Quantitative RT-PCR and Genomic PCR
PAX5 gene expression of ALL samples was quantitated using Taqman® Assayson-demand Hs00277134_m1 (specific for PAX5 exons 4-5) and Hs00172001_m1 (PAX5
exons 7-8) (Applied Biosystems, Foster City, CA). RNA was extracted using TRIzol
(Invitrogen), and reverse transcribed using random hexamer primers and Superscript III
Reverse Transcriptase (Invitrogen). Taqman® assays were performed using a 7500 RealTime PCR system and 7500 System Software (Applied Biosystems, Foster City, CA),
using the 7500 universal cycling conditions: 50°C for 2 minutes, followed by 95°C for 10
minutes, then 40 cycles of 95°C for 1 minute and 60°C for 1 minute.
Standard curves for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
PAX5 gene expression were generated from 10-fold serial dilutions of the human t(12;21)
[ETV6-RUNX1] REH cell line (American Type Culture Collection, Manassas, VA),
which expressed high levels of PAX5 as determined by gene expression profiling using
Affymetrix U133A chips (Affymetrix, Santa Clara, CA) (data not shown). These
normalized ratios were compared to each other for differences in overall levels of PAX5
expression.
Primers for genomic quantitative PCR were designed using Primer Express 3.0
(Applied Biosystems, Foster City, CA). Taqman® RNase P primers (Applied
Biosystems, Foster City, CA) were used for control amplification. 200ng of leukemic
blast DNA or control human DNA was amplified using the same conditions as those
described for RNA real-time PCR. Standard curves for each PAX5 exon and RNase P
were generated using normal human DNA. Assays were performed in duplicate. PAX5
exon-specific copy numbers values were normalized by dividing the value obtained for
PAX5 by the paired value obtained for RNase P for each sample. Cutoffs of 0.7 and 0.3
were used to identify hemizygous and homozygous PAX5 deletions, respectively.
2.2.9 Detection of PAX5 in Leukemic Blasts by Flow Cytometry
We characterized PAX5 expression in bone marrow mononuclear cells obtained
at diagnosis from 16 patients with B lineage ALL. After density gradient separation, cells
were labeled with anti-CD34 (of IgG2a class) conjugated to allophycocyanin (APC;
Miltenyi Biotech, Auburn, CA) and anti-human CD19 (of IgM class; Research
Diagnostics, Concord, MA) followed by goat-anti mouse IgM conjugated to
phycoerythrin (PE; Jackson ImmunoResearch Laboratories, West Grove, PA). After cell
permeabilisation with 8E, a paraformaldehyde-based reagent developed in the laboratory

9

of Dario Campana (SJCRH), cells were labeled with anti-human PAX5 (of IgG1 class;
BD Transduction Labs, San Jose, CA) followed by goat anti-mouse IgG1 conjugated to
fluorescein isothiocyanate (FITC; Southern Biotechnology Associates, Birmingham, AL).
In parallel tests, anti-CD19 was omitted and cells were also labeled with a goat F(ab’)2anti-human IgM PE (Southern Biotechnology Associates, Birmingham, AL) after
permeabilisation. Isotype-matched non-reactive antibodies were used as controls. We
used the cell lines Raji and Kasumi-2 as positive controls for PAX5 staining; Molt-4 and
Jurkat were used as negative controls. We analyzed 20,000 cells for each antibody
combination using a FACSCalibur flow cytometer (BD Biosciences) and either
CellQuestPro (BD Biosciences) or FlowJo (Treestar Inc, Ashland, OR) software.
To show the B-cell specificity of the PAX5 antibody, we examined PAX5
expression in peripheral blood mononuclear cells from a healthy donor. After density
gradient separation, cells were labeled with anti-CD3 (of IgG2a class) conjugated to
Pacific Blue (Invitrogen) and goat F(ab’)2-anti -human IgM PE. After cell
permeabilisation with 8E, cells were labeled with the anti-human PAX5 antibody
followed by goat-anti-mouse IgG1 FITC. In a parallel tube, we used an isotype-matched
non-reactive control antibody (DakoCytomation, Carpinteria, CA) in place of PAX5
followed by goat-anti-mouse IgG1 FITC (Southern Biotechnology Associates). We
analyzed 10,000 cells using an LSR II flow cytometer (BD Biosciences) and
CellQuestPro. The PAX5 antibody stained B-lymphocytes, but not T-lymphocytes.
To demonstrate the PAX5-specificity of the anti-PAX5 antibody, we synthesized
25 12mer overlapping peptides corresponding to the immunogen used to raise the PAX5
antibody (residues 151-306). Peptides were synthesized using an Aapptec 396 Multiple
Organic Synthesizer (Aapptec, Louisville, KY). Peptide purity and quality was assessed
by high performance liquid chromatography (HPLC) and matrix assisted laser desorption
ionization time of flight (MALDI-TOF) mass spectrometry. Peptide sequences are
available upon request. PAX5, CD79A (Dako Cytomation) or mouse IgG1 antibody were
preincubated with 15ng of either the PAX5 peptide pool or a non-PAX5 negative control
peptide (corresponding to an internal sequence of SMAC) and then used to stain either
peripheral blood mononuclear cells (PBMNCs) obtained from a normal donor or the Raji
cell line. The PAX5 peptide pool specifically abolished staining of B lymphocytes by
PAX5 but not CD79A. No blocking was seen with the control peptide and no reactivity
with mouse IgG1 antibody was seen. These results demonstrate the PAX5 specificity of
the anti-PAX5 antibody used for quantitation of leukemic blast intracellular PAX5 levels.
2.2.10 Cloning of PAX5 and EBF1 Wild-Type and Mutant Alleles
Total RNA was extracted from leukemia blast samples using TRIzol (Invitrogen)
and 1g of total RNA was reverse transcribed using Superscript III (Invitrogen). The
coding region of the exon 1a isoform of PAX5 was amplified using primers C282 and
C302, the exon 1b isoform was amplified using primers C317 and C302, and the entire
coding region of EBF1 was amplified using primers C503 and C504 using 1l of cDNA
and the Advantage 2 PCR Kit (Clontech, Mountain View, CA). Thermal cycling
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conditions were 5 cycles of 94°C for 30 sec and 72°C 3 min, followed by 5 cycles of
94°C for 30 sec, 70°C for 30 sec and 72°C 3 min, followed by 25 cycles of 94°C for 30
sec, 68°C for 30 sec and 72°C 3 min. PCR products were sequenced directly and after
cloning into either pCR2.1-TOPO (Invitrogen) or pGEM-T Easy (Promega, Madison,
WI) vectors.
2.2.11 Identification, Detection, and Cloning of PAX5 Translocations
The PAX5-ETV6 [PAX5-TEL] translocation was detected using primers
PAX5ex3-F1 and ETV6ex3-R1 as previously described.43 The coding region of PAX5ETV6 mRNA was amplified using primers C282 and C283. 3’ rapid amplification of
cDNA ends (RACE) was performed using the BD Smart RACE™ amplification kit
(Clontech, Mountain View, CA) according to the manufacturer’s instructions, using the
supplied universal primer mix and gene specific primers C294 (PAX5 exon 3) and C300
(exon 1a). Nested PCR was performed using the supplied nested universal primer, and
nested gene-specific primer C295. PCR products were gel-purified and sequenced
directly and after cloning into pCR2.1-TOPO (Invitrogen). Following identification of
PAX5-FOXP1 and PAX5-ZNF521 [PAX-EVI3] fusions by RACE, translocation-specific
RT-PCR was performed using primers C303 and C304 for PAX5-FOXP1, and C303 and
C309 for PAX5-ZNF521. The coding region of the PAX5-FOXP1 mRNA was amplified
using primers C334 and C335, and PAX5-ZNF521 with primers C326 and C327, using
Phusion™ High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) and the
following thermal cycling parameters: 98°C for 60 seconds, followed by 35 cycles of
98°C for 10 seconds, 72°C for 90 sec (PAX5-FOXP1) or 3 minutes (PAX5-ZNF521)
followed by a final extension step of 72°C for 10 min.
2.2.12 Reporter Assays
The coding regions of the exon 1a isoforms of wild type PAX5 and PAX5
mutations, deletions and fusions were cloned into the XhoI site of the MSCV-IRESmRFP (MIR) vector by blunt-ended ligation. This vector was created by replacing the
green fluorescent protein (GFP) cassette of the MSCV-IRES-GFP vector44 with a
monomeric red fluorescent protein cassette45 (kindly provided by Martine Roussel of St
Jude Children’s Research Hospital, Memphis, TN). Twenty-four hours after plating,
2x105 293T cells were transfected with 1g of wild-type MIR-PAX5, mutant MIRPAX5 or MIR without PAX5 plasmid DNA, 1 g of luc-CD19 reporter plasmid DNA
(kindly provided by Meinrad Busslinger, Vienna, Austria),46 and 0.1 g of pRL-TK
Renilla luciferase plasmid DNA (Promega) using FuGENE 6 (Roche Diagnostics,
Alameda, CA). Forty-eight hours post-transfection, cell lysis and measurement of firefly
and Renilla luciferase activity was performed using the Dual-Luciferase® Reporter
Assay System (Promega) according to the manufacturer’s instructions. Transfections
were performed in triplicate. The firefly luciferase activity was normalized according to
corresponding Renilla luciferase activity, and luciferase activity was reported as mean (±
s.e.m.) relative to the luc-CD19/PAX5 WT transfection. For competition assays, in which
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increasing amounts of either PAX5-ETV6 or PAX5-FOXP1 vector was transfected with
fixed amounts of PAX5 wild type vector, “empty” MSCV-IRES-mRFP vector was also
used to maintain a constant mass of expression vector in each experiment.
2.2.13 Electrophoretic Mobility Gel-Shift Assays
Nuclear extracts of 293T cells transfected with wild type PAX5 or PAX5 mutant
alleles were prepared using the method of Andrews and Faller.47 Equivalent expression of
each PAX5 variant was confirmed by western blotting of nuclear extracts (data not
shown). Two micrograms of protein was incubated with [-32P]ATP end-labeled doublestranded oligonucleotides containing a CD19 promoter PAX5 binding site10 using the Gel
Shift Assay System (Promega). A mutated CD19 binding site was used as a non-specific
competitor. Complexes were supershifted using a PAX5 N-terminus specific rabbit
polyclonal antibody (Chemicon, Temecula, CA) and were resolved using 6% DNA
retardation gels (Invitrogen).
2.2.14 Western Blotting
Four million leukemic blasts were washed with PBS and lysed with 4x LDS
sample buffer (Invitrogen). For nuclear extracts, 10l of nuclear lysate was blotted.
Lysates were separated using NuPAGE 10% Bis-Tris gels, transferred to nitrocellulose
membranes, and after blocking were incubated with N-terminal (Chemicon) or Cterminal PAX5 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), C-terminal
Actin (Santa Cruz), and as a control for blotting of nuclear extracts, N-terminal DEK
antibody (BD Biosciences). Nuclear extracts of 558LM cells were incubated with
PCNA antibody (Santa Cruz). Following incubation with secondary antibody, blots were
developed using the SuperSignal West Femto Max Sensitivity Substrate
chemiluminescent reagent (Pierce, Rockford, IL) and exposed to film or captured using a
ChemiDoc XRS gel imaging system (Bio-Rad Laboratories, Hercules, CA).
2.2.15 Transduction and Analysis of IgM Expression by 558LµM Cells
The terminally differentiated B-cell line 558LM is a derivative of the J558L
plasmacytoma cell line stably transfected with a construct expressing three of four
components required for surface IgM expression: IgM heavy chain, immunoglobulin
lambda light chain, and Ig-The cells do not express mb-1, hence the cells do not
produce Ig- and surface IgM is not expressed. mb-1 expression is dependent on Pax5,
thus following transduction of 558LM cells with ecotropic retroviruses expressing
PAX5, surface IgM expression serves as a useful readout of the transactivating activity of
PAX5 variant alleles.
558LM cells were grown in RPMI 1640 media (Invitrogen) supplemented with
10% fetal bovine serum (Hyclone, Logan, UT), 2mM L-glutamine (Invitrogen), 50mg/ml
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gentamicin (Invitrogen), 0.3g/ml Xanthine (Sigma, St Louis, MO), and 1g/ml
mycophenolic acid (Sigma) as previously described.48 The Phoenix packaging system
was used to generate ecotropic retrovirus expressing PAX5 cloned into either the MSCVIRES-mRFP or MSCV-IRES-YFP constructs, as described above. 500,000 558LM cells
were transduced in six-well dishes with 3 ml of retroviral supernatant and 8g/ml
polybrene. One day post transduction cells were transferred to 10ml of fresh media. Cells
were harvested for flow cytometric analysis and fluorescence activated cell sorting
(FACS) day 3 post transduction.
Samples were stained with fluorescein isothiocyanate conjugated anti-mouse IgM
(Southern Biotechnology Associates, Birmingham, AL) and a rat IgG2a isotype control
antibody (BD Pharmingen) on a FACSVantage SE (BD Biosciences). 100,000 viable
events were collected for analysis. IgM expression was analyzed in the RFP or YFP
positive populations. Two million RFP-positive cells were flow sorted for western
blotting.
2.2.16 Methylation Analysis
Methylation status of the promoter regions of EBF1, PAX5 exons 1a and 1b, and
IKZF1 (Ikaros) was analyzed by matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI-TOF MS) of PCR-amplified, bisulfite-modified leukemic
blast DNA, as previously described (Sequenom, San Diego, CA).49,50 This method allows
semiquantitative, high-throughput analysis of methylation status of multiple CpG units in
each amplicon generated by base-specific cleavage.
Ninety-six samples were examined. PCR reactions were designed using annotated
CpG island data obtained from the University of California Santa Cruz genome browser.
The PAX5 gene contains several CpG islands, one of which (Chr 9:37024136-37028341)
lies upstream of the coding region of PAX5 exon 1a. Two amplicons were used to
examine this region: X014_PAX5 lies immediately upstream of the PAX5 exon 1a coding
region in the known regulatory region of the PAX5 promoter;51,52 X019_PAX5 lies is
further upstream in the same CpG island. Amplicon X021_PAX5 is located in the CpG
island (Chr 9 37016223-37018014) upstream of the coding region of PAX5 exon 1b.
Methylation data for each amplicon was viewed in GeneMaths XT v 1.5 (Applied Maths,
Austin, TX). To compare methylation levels between ALL subtypes, the mean
methylation levels of CpG units in each amplicon was calculated for each patient. Mean
methylation levels for each amplicon were then compared across ALL subtypes by oneway ANOVA, and Dunn’s post-hoc test.
2.2.17 Gene Set Enrichment Analysis
GSEA53 considers the genome-wide expression profiles of two classes of samples
(here, PAX5-mutated and PAX5-wild-type). Genes are ranked based on correlation
between expression and class distinction. GSEA then determines if the members of a
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gene set S are randomly distributed in the ranked gene list L, or primarily found at the top
or bottom. An enrichment score ES is calculated that reflects the degree to which a gene
set is overrepresented at the top or bottom of the entire ranked list L. The ES is a running
sum, Kolmogorov-Smirnov like statistic calculated by walking down list L and increasing
the statistic when a gene in S is encountered, and decreasing it when it is not. The
magnitude of the increment depends on the strength of association with phenotype, and
the ES is the maximum deviation from zero encountered in the random walk. The
significance level of ES is calculated by phenotype-based permutation testing, and when
a database of gene sets are evaluated, as in this analysis, the significance level is adjusted
for multiple hypothesis testing by calculation of a false discovery rate FDR.
2.3 RESULTS
2.3.1 Focal Deletions of EBF1 in B-ALL
Eight B-progenitor ALL cases harbored mono-allelic deletions of EBF1 (early Bcell factor), with deletions limited to this gene in 6 cases (Figure 2-1A-B). EBF1 is
required for the development of B cells, and with E2A regulates the expression of Blineage specific genes. Mice null for Ebf1 arrest B cell development at the pro-B cell
stage, whereas Ebf1+/- mice have a 50% reduction in the number of mature B cells but a
normal number of pro-B cells.54 These observations suggest that EBF1
haploinsufficiency may contribute to leukemogenesis. In support of this interpretation,
FISH analysis of one case revealed two populations of blasts, one with mono-allelic and
the other with bi-allelic EBF1 deletions (Figure 2-1C). Flow cytometric analysis of this
case demonstrated two distinct blast populations, an immature pro-B cell like
CD10dimCD22dim population and a more mature CD10brightCD22+ population (Figure 21D). These populations significantly differed in expression of CD79A (MB-1), a
transcriptional target of EBF1 (Figure 2-1E). Remarkably, FISH on sorted blasts revealed
homozygous deletion of EBF1 in the immature CD10dim fraction, and hemizygous EBF1
deletions in the more mature CD10bright fraction (Figure 2-1F). Thus, these data suggest
that deletion of EBF1 in these cases may contribute to the block in differentiation that is a
hallmark of ALL.
In ALL cases with mono-allelic deletion of EBF1, expression of the wild-type
EBF1 allele was detected by RT-PCR consistent with haploinsufficiency. Moreover, no
evidence of promoter methylation or point mutations of EBF1 was detected (data not
shown).49
2.3.2 A High Frequency of Mono-Allelic PAX5 Deletions in B-ALL
We next examined the cohort for abnormalities in other genes within the B-cell
development pathway. Remarkably, we identified copy number changes in PAX5 in 57 of
192 (29.7%) B-progenitor ALL cases (mono-allelic loss in 53, biallelic loss in 3, and an
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Figure 2-1 EBF1 deletions in B-progenitor ALL
A, EBF1 exons are indicated by vertical lines. The extent of EBF deletion in each case is
shown by a horizontal line, with large deletions denoted by arrowed lines. *FISH analysis
for case BCR-ABL-SNP#5 is shown in C. B, Copy number heatmap showing EBF1
deletion in 8 B-ALL cases. Ph, BCR-ABL1 positive; H, hypodiploid; O, other. C, EBF1
FISH of case BCR-ABL-SNP#5 identifies two distinct blast populations, with either
mono-allelic or bi-allelic EBF1 deletion; the EBF1 probe is red and the control probe is
green. D, Two distinct blast populations differ in surface expression of CD22 and CD10.
E, Correlation of blast CD79A and CD10 expression. F, FISH analysis of cells sorted by
CD10 expression.
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internal amplification in 1, Figure 2-2). PAX5 is essential for B-lineage commitment and
maintenance55 and acts downstream of E2A and EBF1 to activate expression of B-lineage
specific genes such as CD19, CD79A, BLNK and CD7, and to repress expression of
alternate lineage genes.56,57 Four patterns of PAX5 deletion were identified (Figure 2-2B):
(1) focal deletions involving only PAX5 (25 cases), (2) broader deletions involving PAX5
and a variable number of flanking genes (7 cases), (3) large 9p deletions involving the 3’
portion of PAX5, (5 cases) and (4) deletion of all of chromosome 9 or 9p (19 cases). The
PAX5 deletions and amplification were confirmed by FISH and/or genomic qPCR.
Importantly, FISH demonstrated that, with rare exception, the PAX5 deletions were
present in a dominant leukemic clone, consistent with a role in leukemogenesis.
Of 25 B-progenitor ALLs with deletions confined to PAX5, 23 deleted only a
subset of PAX5 exons, resulting in the expression of internally deleted transcripts. In nine
cases, in-frame splicing across the deletions would be predicted to encode an internally
deleted PAX5 protein that either lacks the DNA-binding domain and/or transcriptional
regulatory domains. Western blot analysis in cases with sufficient material revealed
expression of the predicted size mutant PAX5 protein (Figure 2-2 D-E and data not
shown). The other transcripts are predicted to encode prematurely truncated proteins
lacking key PAX5 functional domains. The focal amplification of PAX5 exons 2-5 in
case Hypodip-SNP-#7 is predicted to abolish expression of normal PAX5 from the
amplified allele. Thus, of the 57 cases with PAX5 copy number changes, the majority
either lack expression of PAX5 from the altered allele (27 cases), produce proteins that
lack the DNA-binding domain (22 cases), or transcriptional regulatory domain (7 cases),
or have a bi-allelic promoter mutations (one case), suggesting that these genetic
alterations primarily result in loss-of-function.
Flow cytometry performed on leukemic blasts in 17 cases demonstrated an
approximately twofold reduction in the level of wild-type PAX5 protein in cases with
mono-allelic deletions, suggestive of haploinsufficiency. Consistent with this
interpretation, PAX5 mRNA levels were quantitated in 46 B-ALL cases (26 wild-type, 20
mutated), and were found to be reduced in cases with PAX5 deletions. A small number of
PAX5 wild-type cases also had low PAX5 mRNA levels, raising the possibility of
epigenetic PAX5 silencing in these cases.
2.3.3 Cryptic Translocations and Point Mutations of PAX5 in B-ALL
Five B-progenitor ALL cases had large 9p deletions extending into the 3’ portion
of PAX5. Two had rearrangements of chromosomes 9 and 12, either as a dic(9;12) or a
t(9;12), and were shown by FISH and RT-PCR to harbor the previously described PAX5ETV6 fusion43,58 (Figure 2-3A-B). Rapid amplification of cDNA ends identified novel
PAX5 chimeric transcripts in two of the remaining three cases: fusion of PAX5 exon 6 to
exon 7 of the forkhead box P1 gene (FOXP1), and fusion of PAX5 exon 7 to exon 4 of
the zinc finger protein 521 gene (ZNF521, the human homolog of murine Evi3) (Figure
2-3A). These were confirmed by FISH (Figure 2-3C-D), RT-PCR, and sequencing. The
PAX5-ETV6 fusion was also detected as a 65kDa protein in both cases containing this
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Figure 2-2 PAX5 deletions in ALL
A, PAX5 exons and domains. PD, paired domain; O, octapeptide; H, homeodomain-like;
TD-A, transactivation, activating; I, transactivating, inhibitory. B, Extent of PAX5
deletions: hemizygous, solid line; homozygous, dashed; amplification, red; beyond region
shown, arrowed; *deletion confined to PAX5. C, PAX5 copy number heatmap for 20
ALL cases and corresponding germline samples. PAX5 exon-specific copy number as
defined by quantitative genomic PCR is also shown. Amp, amplified; CN, copy number;
T-P, TCF3-PBX1; H, homozygous; N, normal (remission sample); Ph, BCR-ABL1; T, TALL. D-E, Schematic of PAX5 mutations and western blot of primary leukemic blasts
(mutant PAX5 proteins indicated by arrows).
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Figure 2-3 PAX5 translocations in B-progenitor ALL
A, Schematic of PAX5 translocation-encoded fusion proteins. Breakpoints are indicated
by (↓); bp, base pairs; BRE, BMP2 response element domain; EBF, EBF-interaction
domain; ETS, Ets domain; C and CC, coiled-coil domain; FH, forkhead domain; H,
homeodomain-like; HLH, helix-loop-helix; O, octapeptide domain; PD, paired domain;
SMAD, SMAD-interacting domain; Zn, zinc finger domain. B-D, Interphase FISH for
PAX5-ETV6 (B), PAX5-FOXP1 (C) and PAX5-ZNF521 (D). The PAX5-specific probe is
red, and the partner genes green; arrows denote the fusions. e, Location of missense (▼),
insertion/deletion (●), frameshift (♦) and splice-site (►) PAX5 mutations.
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rearrangement (Figure 2-2E); primary patient material was not available for western blot
analysis for the PAX5-FOXP1 and PAX-ZNF521 cases. An additional 50 cases were
screened by RT-PCR for the three translocations and no additional cases were identified.
Each of these PAX5 chimeric genes fuse the DNA-binding paired domain of
PAX5 to the DNA-binding and transcriptional regulatory domains of the partner proteins
(Figure 2-3A). Thus, the fusion proteins are predicted to retain the ability to bind to
PAX5 transcriptional targets, but would no longer provide normal transcriptional
regulatory functions. The fusion proteins may also influence the expression of genes
normally regulated by the partner protein, each of which has been implicated in B cell
development or hematopoietic malignancies.59-63
Sequencing of PAX5 identified point mutations in 14 cases that clustered in exons
encoding the DNA-binding or transcriptional regulatory domains (Figure 2-3E). In 13
cases with available germline DNA, the mutations were shown to be somatically
acquired. Moreover, a quantitative analysis suggested that the mutations were present in
all blasts in 12 of 14 cases, and in a major subclone in the remaining two cases. The point
mutations were hemizygous except in one case where a homozygous splice-site mutation
(IVS9+1) of PAX5 was detected within an extensive region of 9p LOH that included a
homozygous deletion of CDKN2A.
Nine PAX5 mutations were identified within exons encoding the paired DNAbinding domain: V26G, P34Q, P80R, and the insertion/deletion NDTVP126RA (Figure
2-3E). Modeling studies using the PAX5 crystal structure41 suggests that each mutation
should impair DNA-binding. Other mutations consist of frame-shift, splice site, or
missense mutations that affect the transactivation domain, and a single case with an exon
1B frame-shift mutation that results in a prematurely truncated 10 residue polypeptide
(Figure 2-3E). Collectively, the identified PAX5 mutations are predicted to result in lost
or altered DNA-binding or transcriptional regulatory function.
We also assessed whether methylation-induced silencing of PAX5 occurs in Bprogenitor ALL using mass spectrometry.10 These data revealed high-level PAX5
promoter methylation in T-ALL, but minimal methylation in B-progenitor ALLs,
irrespective of PAX5 mutational status. Thus, epigenetic silencing due to high-level
methylation does not appear to be a prominent mechanism of PAX5 silencing in Bprogenitor ALL.
2.3.4 Functional Consequences of PAX5 Mutations
To assess the DNA-binding and transcriptional activity of a subset of the
identified PAX5 mutants, luciferase-based reporter assays were performed using the
PAX5-dependent reporter plasmid, luc-CD19.46 Each of the PAX5 mutants tested
displayed significantly reduced transcriptional activation compared to wild-type PAX5
(Figure 2-4 A-B and Figure 2-5). Moreover, transfection of increasing amounts of PAX5ETV6 or PAX5-FOXP1 together with a fixed amount of wild-type PAX5 demonstrated
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Figure 2-4 Impaired function of PAX5 mutants
A, Structure of PAX5 variants. B, transcriptional activity of PAX5 variants using the lucCD19 reporter. Bars show mean (± s.e.m.) luciferase activity of triplicate experiments
normalized to luciferase activity of wild-type (WT) PAX5. **ANOVA with Dunnett’s
test P<0.01 c.f. WT PAX5. C, representative flow plots of 558LM cells transduced with
PAX5-expressing retrovirus, showing reduced sIgM expression of PAX5 mutants c.f.
WT PAX5. Percents indicate proportion of mRFP+ cells that are sIgM+. D, mean (±
s.e.m.) 558LM sIgM expression of triplicate experiments, normalized to sIgM
expression of PAX5 WT transduced 550LM cells. E, Impaired sIgM expression is
corrected following co-infection with WT PAX5 virus (WT) for the PAX5 deletion and
point mutants, but not PAX5-ETV6.
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Figure 2-5 PAX5 western blots of 293T cells used for CD19-luc reporter assays
Western blots using an N-terminus PAX5 specific antibody (Chemicon) were performed
on nuclear extracts of transiently transfected 293T cells. Neither this antibody, nor any of
the alternative available PAX5 specific antibodies detect the PAX5 Δ2-6 or Δ2-8 internal
truncation mutants.

21

that the fusion proteins competitively inhibit the transcriptional activation of wild-type
PAX5 (Figure 2-6). Analysis of DNA-binding activity revealed a marked reduction in
binding activity for PAX5 variants with paired domain mutations or deletions (Figure
2-7).
We next examined the effect of PAX5 mutations on transcriptional activation of
the PAX5 target Cd79a (mb-1, Ig-) in the murine plasmacytoma cell line 558LM.23
This cell line expresses three of four components of the surface IgM (sIgM) receptor
complex ( heavy chain,light chain, and Ig-), but not Cd79a or Pax5, and consequently
does not express sIgM. Following transduction with PAX5-expressing retrovirus, Cd79a
and thus sIgM are expressed, and quantitation of sIgM serves as a sensitive measure of
the Cd79a transactivating activity of PAX5.48 This assay confirmed the reduced
transcriptional activity of the PAX5 mutants (Figure 2-4C-D and Figure 2-8). Cotransduction with wild-type and mutant PAX5 retroviruses showed that PAX5 wild-type
virus restored sIgM expression in the presence of the P34Q, P80R or 6-8 PAX5 variants,
but incompletely with PAX5-ETV6 (Figure 2-4E and Figure 2-9). This suggests that the
PAX5 DNA-binding and internal deletion mutants act as hypomorphic alleles with weak
competitive activity, where as PAX5-ETV6 acts as a stronger competitive inhibitor of
wild-type PAX5.
As the PAX5 mutations are predicted to reduce or inhibit normal PAX5 functional
activity, we next examined expression of PAX5 target genes in leukemic blasts. We did
not observe a correlation between PAX5 mutation status and expression of the PAX5
targets CD19 and CD79A.11,57 However, using Affymetrix HG-U133A gene expression
profiling data,64 we identified a 42 gene expression signature for PAX5-mutated ETV6RUNX1 B-ALL that included both up-regulated (PAX5 repressed) and down-regulated
(PAX5 stimulated) genes (Figure 2-10A). PAX5-stimulated genes included the known
PAX5 target CD7257 as well as genes with known roles in oncogenesis (e.g. DAPK1,65
TACC166). We then performed cross-subtype gene set enrichment analysis (GSEA)53 to
test for enrichment of these putative PAX5-regulated genes in non-ETV6-RUNX1 B-ALL
cases. This analysis demonstrated highly significant enrichment of the PAX5 stimulated
genes in PAX5 wild-type B-progenitor ALL cases that lacked recurrent cytogenetic
abnormalities, and in PAX5 wild-type cases from the entire non-ETV6-RUNX1 Bprogenitor ALL cohort (Figure 2-10B-C). This suggests that the identified PAX5
mutations have a significant effect on the intracellular transcriptional network within
primary leukemic cells.
2.3.5 Pattern of B-Cell Development Gene Mutations in ALL
Deletions of additional genes encoding regulators of B-cell development were
identified, including IKZF1 (Ikaros, 17 B-progenitor ALL cases), IKZF3 (Aiolos, N=3),
LEF1 (N=3) TCF3 (N=1) and BLNK (N=2). Genomic sequencing of IKZF1 was
performed in all cases and no mutations were identified.
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Figure 2-6 PAX5 translocations competitively inhibit the transcriptional activity of
wild-type PAX5
Relative luminescence of 293T cells transfected with luc-CD19, fixed amount of PAX5
WT and increasing amounts of PAX5-ETV6, A, or PAX5-FOXP1, B, plasmids. Empty
MSCV-IRES-mRFP (MIR) expression vector was used to maintain a constant mass of
DNA in each transfection experiment. Luminescence is normalized to Renilla luciferase
activity and is shown relative to 293T cells infected with empty MIR vector. Bars show
means ± SEM of triplicate experiments. *ANOVA with Dunnett’s test P<0.05; **P<0.01.
Importantly, expression of the various PAX5 mutants did not inhibit the transcription of
the pRL-TK Renilla luciferase plasmid used as an internal control for transfection
efficiency.
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Figure 2-7 DNA-binding of PAX5 mutant alleles
Gel-shift assay showing reduced (P80R) and normal (6-8) binding of PAX5 variants to
a CD19 promoter binding site. ab, supershift with PAX5 antibody; wt, wild-type and mt,
mutant competitor oligonucleotides; -, no antibody or competitor oligonucleotides.
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Figure 2-8 PAX5 mutations impair CD79A transactivation of sIgM expression in the
558LµM cell line
558LM cells were transduced with MSCV-PAX5-IRES-mRFP retroviruses expressing
wild type or mutant PAX5. sIgM expression of the mRFP-positive population was
measured. Four experiments examining different PAX5 variants were performed (A-E,
F-J, K-P and Q-T). Empty vector (MIR) and wild-type PAX5 (PAX5 WT) were
included as controls in each experiment. All transductions were performed in triplicate,
and representative flow plots are shown. Percentages refer to the proportion of RFP+
cells expressing sIgM. Two million RFP+ cells were sorted from a transduction
experiment for each PAX5 variant, and western blotting for PAX5 and the control
antigen PCNA performed on nuclear extracts of the RFP+ population. Sort purities were
>90%. Western blot analysis confirmed comparable protein expression of the PAX5
variants analyzed, with the exception of PAX5-ETV6, which is larger than the other
variants (approx. 65kDa c.f. 45 kDa for WT PAX5), and is consistently expressed at
lower protein levels than the other variants. The PAX5 antibody used (BD Transduction
Labs) was raised against an internal PAX5 epitope and does not recognize the 2-6 or
2-7 PAX5 internal deletion mutants shown in P.
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Figure 2-9 Design of 558LµM PAX5 WT and mutant co-transduction experiments
558LM cells were co-transduced with bicistronic MSCV retroviruses co-expressing
wild type PAX5 with YFP, and mutant PAX5 alleles with mRFP. Surface IgM
expression was then quantitated on the dual positive population.
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Figure 2-10 Cross-subtype gene set enrichment analysis of PAX5-regulated genes in
B-ALL
A, heatmap of 42 differentially expressed genes (at FDR <0.3) in ETV6-RUNX1 PAX5deleted v. ETV6-RUNX1 PAX5 wild-type ALL. B, GSEA showing significant enrichment
of the PAX5-stimulated genes shown in B-ALL samples lacking recurring cytogenetic
abnormalities. The ranked gene list of PAX5-wild-type v. PAX5-deleted cases is shown in
the lower, grey plot. Vertical blue lines indicated where probe sets in the PAX5stimulated gene set fall in the ranked gene list. The top, red line indicates the running
enrichment score (ES) that becomes more positive as probe sets are encountered at the
top of the list. C, significant enrichment for PAX5-stimulated genes in all non-ETV6RUNX1 B-progenitor ALL. Enrichment for the PAX5-repressed gene set in PAX5mutated cases was also observed in both non-ETV6-RUNX1 cohorts, but was not
significant (i.e. FDR>0.25) after correction for multiple hypothesis testing.
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Importantly, there were marked differences in the frequency and type of
mutations among genetic subtypes of ALL. Specifically, all 10 hypodiploid cases had one
null PAX5 allele, and six of these also had either a point mutation (N=5) or translocation
(PAX5-ZNF521, N=1) involving the other PAX5 allele. Five of these cases also contained
deletions in other B-cell development genes, with up to three different genes being
mutated within a single case. In contrast, 28% of the ETV6-RUNX1 cases contained focal
mono-allelic PAX5 deletions but lacked evidence of mutations in the retained PAX5
allele. Three of these cases also had deletions of a single allele of EBF1, and another two
cases had deletions of only EBF1. At the other end of the spectrum, mutations in B-cell
development genes were uncommon in hyperdiploid B-progenitor ALL (13% of cases).
2.4 DISCUSSION
Understanding the molecular pathogenesis of cancer requires a detailed
cataloguing of all genetic lesions within a cancer cell. The data presented here provide a
rational roadmap for approaching such a task. We have shown that genomic copy number
analysis using high-density SNP arrays can pinpoint altered genes and pathways for
further analysis. This approach led to the unexpected finding of mutations in genes
encoding regulators of B cell development and differentiation in 40% of B-progenitor
ALLs. The identified genetic alterations are specific, pathogenic, and somatically
acquired. In addition, the majority of EBF1 and PAX5 deletions affect only these genes,
thus conclusively identifying them as the target of the deletions. Moreover, the average
number of deletions within an individual B-ALL case was 3.83, and focal amplifications
were uncommon, suggesting global genomic instability is not an underlying mechanism.
Lastly, although somatic point mutations were identified in PAX5, sequencing of EBF1
and Ikaros failed to reveal any evidence of mutations, ruling out a high mutational rate.
The most common targets of these genetic alterations (EBF1, PAX5, and Ikaros)
play central roles in the development of normal B-cells.56 In mice the complete absence
of Ebf1 or Pax5 results in the arrest of B-cell development at the early pro-B or pro-Bcell stage,54,55 and loss of Ikaros leads to an arrest at an even earlier stage of lymphoid
development.67 Moreover, haploinsufficiency of Ebf1 leads to a partial block in B cell
development,54 a phenotype that is further accentuated in mice haploinsufficient for both
Ebf1 and E2a.68 In addition, loss of Ikaros through the expression of a dominant negative
Ikaros isoform predisposes mice to the development of T-lineage malignancies.69
The overall consequence of the identified lesions is to reduce the level of the
specific transcription factor either as a result of mono-allelic deletion or the generation of
altered forms of the specific protein. Whether some mutations result in dominant negative
forms of PAX5, or alternatively alter transcriptional activity in a promoter specific
manner requires further investigation. It is important to note that during the normal
development of B-cells, PAX5 is subjected to allele-specific regulation, with only a single
PAX5 allele transcribed during the earliest phase of B-cell commitment and then a switch
to bi-allelic expression as B-cells begin to differentiate.70 The loss of a wild-type PAX5
allele from the identified mutations would eliminate the ability to turn on normal bi-
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allelic transcription, which may directly contribute to the differentiation arrest seen in
ALL.
Members of the PAX family of transcription factors including PAX3, PAX7, and
PAX8 have previously been identified as targets of tumor-associated translocations71 that
result in the over-expression of PAX fusion proteins. In addition, over-expression of
wild-type PAX5 occurs as a result of its rearrangement into the IGH locus in nonHodgkin lymphoma.72 In sharp contrast to over-expression, however, our results
implicate subtle changes in the dosage of PAX5 and other key regulators of B-cell
development in the pathogenesis of ALL. Although heterozygous alterations of PAX5
may have only subtle effects on their own, these effects are likely to contribute directly to
leukemogenesis in combination with other oncogenic lesions.
The identified high frequency of alterations of B-cell development genes in
pediatric B-progenitor ALL represents a lower limit of the true frequency. Direct copy
number analysis of those genes with low density SNP coverage along with full sequence
analysis of all genes involved in controlling B-cell development and differentiation will
be required to define the overall frequency. Nevertheless, our results demonstrate an
unexpectedly high frequency with distinct patterns of mutations among the various
genetic subtypes of pediatric ALL. Experiments to directly assess the effect of coexpressing PAX5 mutants and fusion proteins such as ETV6-RUNX1 in murine models
should provide valuable insights into the ability of these lesions to collaborate in
leukemogenesis. Moreover, attempts to determine whether small molecule inducers of
differentiation can bypass the block resulting from the identified lesions, and whether
these molecules in turn would trigger a leukemia cell-specific apoptotic response, could
lead to new therapeutic approaches for pediatric ALL.
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CHAPTER 3
Pax5 HAPLOINSUFFICIENCY COOPERATES WITH BCR-ABL1 TO INDUCE
ACUTE LYMPHOBLASTIC LEUKEMIA
3.1 INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy
and is comprised of several distinct genetic subtypes including B-progenitor leukemia’s
with t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], rearrangements
of MLL, and hyperdiploid or hypodiploid karyotypes, and T-lineage leukemias.1 These
defining genetic lesions play a role in disease initiation,6 but alone are insufficient to
generate overt leukemia. In an effort to identify cooperating oncogenic lesions, we
recently performed genome-wide copy number and loss-of-heterozygosity (LOH)
analyses on over 400 pediatric ALL leukemias.7 These analyses identified somatic
mutations in genes encoding regulators of B-cell development and differentiation in over
40% of B-progenitor ALLs. The most common targets of these loss-of-function
mutations were the transcription factors PAX5, IKZF1, and EBF1, with PAX5 being
mutated in over 30% of patients. Notably, BCR-ABL1 ALL was characterized by a high
frequency of mutations of IKZF1 (85%), PAX5 (55%), and CDKN2A/B (encoding
INK4A/ARF and p15, 55%), suggesting that these lesions cooperate with BCR-ABL1 in
lymphoid leukemogenesis.19
The mutations of B cell development genes are hypothesized to contribute to
leukemogenesis by inducing a block in the differentiation of the leukemic cells.
Consistent with this hypothesis, the most frequent target of these mutations, the PAX5
transcription factor, is essential for normal B cell differentiation with loss of the gene
resulting in a complete arrest at an early pro-B cell stage of development in the bone
marrow of Pax5-deficient mice.16 PAX5 normally functions by restricting the
multilineage potential of early lymphoid progenitors to the B cell pathway by repressing
lineage-inappropriate genes and activating B cell–specific genes such as CD79a, CD72,
CD19, and BLNK.15,73,74 Moreover, continued expression of PAX5 is required for
maintenance of cells to the B cell lineage. For example, conditional deletion of Pax5 in
committed murine Pro-B cells results in their reversion to a multipotent state from which
T lymphocytes and macrophages can be generated.18 Thus, PAX5 serves as a master
regulator controlling the normal commitment and differentiation of hematopoietic
progenitors to the B cell lineage.
The genomic data, supporting a role for altered PAX5 expression in the
pathogenesis of pediatric ALL, are diverse and include mono-allelic deletions of the
entire gene, focal deletions leading to the expression of hypomorphic PAX5 isoforms,
chromosomal translocations producing PAX5 fusion proteins, and PAX5 DNA sequence
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alterations that result in missense mutations of conserved residues in the DNA-binding
domain, or nonsense, frame shift, or splice site mutations in the transcriptional regulatory
domains.7 Despite these strong human genomic data, mice heterozygous for a Pax5 null
allele show no significant immune system abnormalities and fail to develop B lineage
leukemias during their lifetime.16 The absence of an overt phenotype within mice raises
the possibility that the PAX5 alterations detected in pediatric ALL are bystander or
passenger mutations, and are not mechanistically involved in the development or
maintenance of the leukemic clone. To directly assess the contribution of a reduction in
Pax5 expression to leukemogenesis, we assessed the susceptibility of Pax5+/- mice to
BCR-ABL1-induced lymphoid leukemia. Our data demonstrates that haploinsufficiency
of Pax5 renders mice susceptible to the development of ALL, and directly cooperates
with the loss of the tumor suppressor gene Arf in BCR-ABL1-induced lymphoid
leukemogenesis.
3.2 MATERIALS AND METHODS
3.2.1 Mice
Wild type, Pax5+/-, and Arf+/-, as well as intercrosses of these genotypes were
maintained on a C57BL/6 background. All animal experiments were performed
according to St. Jude Children’s Research Hospital Institutional Animal Care and Use
Committee-approved protocols.
3.2.2 Bone Marrow Transduction and Transplantation Analysis
All bone marrow transplant experiments were performed as previously
described.75 The Murine Stem Cell Virus (MSCV) retroviral expression construct
containing the p185 isoform of BCR-ABL1 (MSCV-GFP-IRES-p185 was provided by O.
Witte (University of California, Los Angeles). The p185 BCR-ABL1 cDNA cassette was
removed from this virus and recloned into a variant version of this vector such that the
BCR-ABL1 gene was cloned 3’ of the GFP gene with an internal ribosomal entry site
(IRES) positioned between the cDNAs (MSCV-GFP-IRES-p185 BCR-ABL1).
Replication-incompetent, ecotropic retrovirus was made by transient transfection of
Phoenix-Eco packaging cells (G. Nolan, Stanford University, Stanford CA) using
previously described methods. Bone marrow (BM) cells were harvested from Pax5+/+,
Pax5+/-, Arf+/-, and Pax5+/-Arf+/- mice and transduced in suspension for 3 hours with
MSCV-GFP-IRES-p185 BCR-ABL1 retrovirus. Cells were washed and injected (2 x 106
per mouse) into lethally irradiated (11Gy in two doses) wild-type C57BL/6 recipient
mice. Mice were observed daily for signs of disease and necropsies were performed on
all moribund animals.
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3.2.3 Histology
Tissues were fixed in 10% buffered formalin, embedded in paraffin, and sections
were stained with hematoxylin and eosin. Cytospins were prepared by centrifuging 1 x
105 BM cells onto a microscope slide using a Wescor cytocentrifuge 7620 (Logan, UT).
Cytospins were stained with Wright’s stain.
3.2.4 FACS Analysis and Cell Sorting
All antibodies were obtained from BD Biosciences (San Jose, CA). Flow
cytometric analysis was performed using a BD LSR II (BD Biosciences) and the
following antibodies: B220-APC, CD43-biotin/SA-PE-Texas Red, CD19-APC-Cy7,
BP1-PE, and IgM-PE-Cy7. Leukemias that were less than 80% GFP positive in the BM
were subject to sorting for GFP positive cells using a FACSAria cell sorter (BD
Biosciences).
3.2.5 Genomic DNA Extraction and Southern Blot Analysis of Proviral Integrations
Genomic DNA was isolated from leukemia cells by proteinase K digestion
followed by phenol:chloroform:isoamylalcohol extraction and ethanol precipitation as
previously described. DNA was quantified using a NanoDrop spectrophotometer and its
quality assessed using agarose gel electrophoresis. The number of proviral integrations in
selected tumors was determined by Southern Blot Analysis. Briefly, 3 micrograms of
genomic DNA was digested with HindIII, separated on a 0.7% agarose gel, and
transferred to a Hybond N+ membrane (Amersham Biosciences). The membrane was
hybridized with a 32P-radiolabeled 724bp NcoI/NotI DNA fragment DNA probe,
corresponding to the GFP cDNA.
3.2.6 Western Blotting
Five million leukemias cells were washed with PBS and lysed with 4x LDS
sample buffer (Invitrogen). 15ul of lysate was separated on NuPAGE 4-12% Bis-Tris
gels, transferred to nitrocellulose membranes, and after blocking were incubated with
either an N-terminal Pax5 antibody (Chemicon, now Millipore, Billerica, MA) or a p19
Arf antibody (Abcam, Cambridge, MA). Following incubation with secondary
antibodies, blots were developed using the SuperSignal West Femto Max Sensitivity
Substrate chemiluminescent reagent (Pierce, Rockford, IL), and images were captured
using the ChemiDoc XRS gel imaging system (Bio-Rad Laboratories, Hercules, CA).
Membranes were subsequently stripped, blocked and reprobed with a C-terminal Actin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as a loading control.
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3.2.7 Array-based Comparative Genomic Hybridization
The Agilent (Santa Clara, CA, USA) eArray 5.0
(https://earray.chem.agilent.com/earray/) platform was used to design microarrays for
CGH analysis. Two separate arrays were designed: For the first array, we used Agilent’s
Mouse Genome CGH Microarray 244A and removed all probes located to chromosomes
X and Y. The vacated space was filled in with 17,573 custom 60-mer oligonucleotide
probes that covered at a 250 bp resolution, twenty genes that are the most frequent targets
of CNAs in human BCR-ABL1 ALL. The coverage of these 20 genes included 100kb
upstream and downstream of their annotated exons. For the second array, we
incorporated 238,382 60-mer oligonucleotide features from across the mouse genome
(excluding features chromosomes X and Y) along with an additiona 5,099 control
features selected from the eArray library. The combination of 476,623 features provides a
median feature spacing of 4,453 bp (the number of features and median spacing for each
individual chromosome are listed in Supplementary Table 8). The arrays were printed
using the Agilent Sureprint technology using in situ oligonucleotide synthesis.
3.2.8 Quantitative Genomic Real-time PCR
Confirmation of copy number abnormalities using genomic quantitative real-time
PCR (gqPCR) was performed for Pax5, Cdkn2a/b, Ikzf3, Ebf1, Zfp456, and V1rf2.
3.2.9 Genomic Resequencing of Pax5
Genomic resequencing of all the coding exons of Pax5 was performed on the 50
leukemia samples analyzed by array CGH. Genomic DNA was extracted as previously
described and each exon was PCR amplified using 1U of AccuPrime GC-Rich DNA
polymerase (Invitrogen, Carlsbad, CA), and 0.2µM forward and reverse primers. Primer
sequences are available upon request. PCR products were purified and then sequenced
directly using Big Dye Terminator (v3.1) chemistry on a 3730xl DNA Analyzers
(Applied Biosystems, Foster City, CA). Mutations detected by direct sequencing were
validated by cloning PCR products in pGEM-T easy (Promega, Madison, WI) and
multiple clones sequenced in both directions with M13 primers.
3.2.10 Structural Modeling of Pax5 Mutations
A structural view of the PAX5 paired domain was generated by PyMOL v0.99
(http://pymol.sourceforge.net/) using the coordinates of the X-ray structure of PAX5
interacting with ETS1 on DNA, and PAX6 deposited with the Brookhaven Data Bank
(PDB: 1K78 and 6pax; http://www.rcsb.org/pdb/).41,42 The protein sequences of the
paired domains of PAX6 and PAX5 are 70.1% identical.
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3.2.11 Gene Expression Profiling
RNA was extracted as previously described76 from the leukemic bone marrow of
10 Pax5+/+, 5 Pax5+/- mice, as well as 5 Pax5+/- mice that later lost their second Pax5
allele. Additionally, all leukemias with a bone marrow % GFP less than 80% were flow
sorted to enrich the sample to greater than 95% GFP positive cells. In addition, RNA was
extracted from flow sorted normal hematopoietic cell subpopulations representing Hardy
fractions A-F (at least 5 individual animals were used as biological replicates for each
fraction) from the bone marrow of Pax5+/+ and Pax5+/- mice. Flow sorted cells from
Hardy fractions A and B were also obtained from Pax5-/- mice (5 samples from each
fraction). The antibodies and sorting strategy used are outlined in detail in a previous
methods section. The quality of the RNA was assessed using the Agilent Bioanalyzer
(Agilent, Santa Clara, CA). Samples were hybridized to Affymetrix 430v2.0 microarrays
(Affymetrix, Santa Clara, CA) as previously described.77
Probe intensities were generated using the MAS 5.0 algorithm, probe sets called
absent in all samples were excluded, and expression data was log-transformed. To define
the gene expression signature of mouse BCR-ABL1, we used Limma (Linear Models for
Microarray Analysis)78, the empirical Bayes t-test implemented in Bioconductor79 and the
Benjamini-Hochberg method of false discovery rate (FDR) estimation80 to identify probe
sets differentially expressed between mouse BCR-ABL1 and normal B-cells.
Principal component analyses were performed using Gene Expression Explorer
v1.1 (Qlucore AB, Lund, Sweden). In addition to conventional PCA analyses, this
program enables PCA to be performed on a selected set of samples (in our case Hardy
fractions A-F) and then applying these principal components on another set of samples
(in our case the leukemias), without letting the second set of samples contribute to the
calculation of the three principal components. This allows diverse samples to be analyzed
together and provides a powerful tool for investigating similarities between normal and
malignant cells that cannot be revealed otherwise.81
3.2.12 Gene Set Enrichment Analysis
To search for enrichment of specific transcriptional programs in the various
normal Hardy fractions and leukemias, gene set enrichment analyses53 were performed.
Gene sets of the top up- and down-regulated genes in the signatures of mouse BCR-ABL1
and Core ESC-like Module were created and added to the collection of currated gene sets
available at the Molecular Signatures Database (http://www.broad.mit.edu/gsea/msigdb/).
GSEA of mouse leukemia and human BCR-ABL1 were then performed using this
expanded collection of gene sets. GSEA then determines if the members of a gene set
(here a Core ESC-like Module) are randomly distributed in the ranked gene list, or
primarily found at the top or bottom. Occurrences of members of the gene set in the
ranked gene list are shown as vertical black lines above the ranked signature. An
enrichment score (ES) is calculated that reflects the degree to which a gene set is
overrepresented at the top or bottom of the entire ranked list. The ES is a running sum,
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Kolmogorov-Smirnov like statistic calculated by walking down list L and increasing the
statistic when a gene in S is encountered, and decreasing it when it is not. The magnitude
of the increment depends on the strength of association with phenotype, and the ES is the
maximum deviation from zero encountered in the random walk, and is depicted as a red
curve. The "leading edge" genes are those members of the gene set responsible for the
observed enrichment, and are those hits occurring to the left of the vertical dotted red
line. The significance level of ES is calculated by phenotype-based permutation testing,
and when a database of gene sets are evaluated, as in this analysis, the significance level
is adjusted for multiple hypothesis testing by calculation of a false discovery rate (FDR).
3.3 RESULTS
3.3.1 Haploinsufficiency of Pax5 Renders Mice Susceptible to B-ALL
Mice hemizygous for a Pax5 null allele (Pax5+/-) have normal adult B cell
development and fail to spontaneously develop leukemia. To directly assess whether the
loss of one allele of Pax5 can cooperate with a known oncogenic lesion in B cell
transformation, we directly assessed the ability of Pax5 haploinsufficiency to cooperate
with the expression of the t(9;22) encoded BCR-ABL1 oncogene, a combination of
lesions that is detected in greater than 50% of pediatric BCR-ABL1 ALL cases. Bone
marrow cells from untreated wild-type (Pax5+/+) or Pax5+/- mice were transduced with a
MSCV-GFP-IRES-BCR-ABL1 (p185) retrovirus designed to express a low level of the
BCR-ABL1 oncogene from an internal ribosomal entry site. Two million unsorted
transduced cells were transplanted after minimal ex vivo manipulation into cohorts of
lethally irradiated C57BL/6J recipient mice (Figure 3-1A). Expression of BCR-ABL1 in
bone marrow cells from wild type mice induced a pre-B cell lymphoblastic leukemia
(B220+, CD43+, CD19+ and BP1+) in recipient animals with a median survival of 60 days
post transplant (Figures 3-1B-C; Figure 3-2A). By contrast, mice transplanted with BCRABL1 expressing Pax5+/- cells developed leukemia with significantly decreased latency
(median survival of 36 days) and increased penetrance (Figure 3-1B). Interestingly, the
leukemias that developed from Pax5+/- cells had a more immature B progenitor
phenotype, with the majority containing a mixture of Pre-B cells and Pro-B cells
characterized by reduced or absent BP1 expression (Figure 3-2B; Figure 3-3). Moreover,
19% of the BCR-ABL1 Pax5+/- leukemias had a very immature Pre-Pro-B cell phenotype
(B220+, CD43+, CD19-, BP1-) (Figure 3-2C; Figure 3-3), a phenotype that was observed
in only a rare BCR-ABL1 Pax5+/+ leukemia.
The primary leukemias that developed from Pax5+/+ and Pax5+/- cells were
transplantable into sublethally irradiated secondary recipients and resulted in the rapid
development of overt leukemia with a phenotype identical to that seen in the donors.
Southern blot analysis to assess the clonality of retroviral integrations revealed the vast
majority of both the Pax5+/+ and Pax5+/- leukemias to be monoclonal, irrespective of
their relative stage of B cell differentiation (Figure 3-2D; Figure 3-4; Table 3-1).
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Figure 3-1 Pax5 haploinsufficiency cooperates with BCR-ABL1 to induce ALL
A, Structure of the retroviral vector used to transduce bone marrow and a schematic
representation of the transduction protocol. Briefly, Pax5+/+ and Pax5+/- bone marrow
was harvested and transduced with the MSCV-GFP-IRES-BCR-ABL1 retroviruses and
transplanted into lethally irradiated C57BL/6J animals. B, Kaplan-Meier survival curves
from a representative experiment of mice transplanted with MSCV-GFP-IRES-BCRABL1 transduced Pax5+/+ or Pax5+/- bone marrow. Leukemias developed in the Pax5+/mice with a decreased latency when compared to Pax5+/+ tumors P=0.0003 (BreslowGehan-Wilcoxon test). Similar results were observed in 4 independent retroviral
transductions and transplantations experiments with between 10 and 20 mice per group.
C-D, Bone marrow from Pax5+/+ (C) and Pax5+/- (D) tumors, stained with HematoxylinEosin. Insets, cytospins of bone marrow stained with Wright Giemsa stain.
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Figure 3-2 Immunophenotype and clonality analysis of BCR-ABL1 induced
leukemias
A, Representative FACS analysis of BCR-ABL1/Pax5+/+ leukemias using antibodies
against B220, CD43, CD19, and BP1. B, Representative FACS analysis demonstrating
the predominant immunophenotype seen in the BCR-ABL1/Pax5+/- leukemias. C,
Representative FACS analysis of the immature pre-pro-B cell leukemias identified in
19% of the BCR-ABL1/Pax5+/- leukemias. D, Southern blot analysis of HindIII digested
genomic DNA from Pax5+/+and Pax5+/- leukemias hybridized with a 724bp GFP probe.
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Figure 3-3 Leukemia immunophenotypes
A, Schematic representation of the pathway followed for flow analysis of Pax5 tumors. A
live cell gate was drawn using Forward Scatter-Area (FSC-A) and DAPI. A gate was
drawn around single cells. Only cells that are GFP positive are analyzed by creating a
GFP gate. B, Pax5+/+, Pax5+/-, p19Arf+/-, and Pax5+/-p19Arf+/- representative tumors are
shown revealing the various immunophenotypes identified in each of the tumor groups.
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Figure 3-4 Assessment of leukemia clonality
Southern Blot Analysis of 3 independent experiments is represented. These blots reveal
that Pax5+/+ and Pax5+/- tumors are monoclonal while p19Arf+/- and Pax5+/-p19Arf+/tumors are oligoclonal. C=control.
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Table 3-1 Clonality analysis of BCR-ABL1-induced leukemias
Leukemia genotype (N)
Pax5+/+ (7)
Pax5+/- (14)
Arf+/- (17)
Pax5+/-Arf+/- (7)

Mono*
7
12
5
0

Oligo†
0
2
12
7

*

Mono signifies one band by Southern blotting of genomic from bone marrow cells that
were either ≥90% GFP+ or if less than 90% was sorted for GFP+ cells;
†
Oligo signifies ≥2 bands by Southern blot analysis.

43

To ensure that the increased susceptibility of Pax5+/- mice to leukemia was not
restricted to BCR-ABL1-induced disease, a cohort of young Pax5+/+ (N=20) and Pax5+/(N=25) mice were thymectomized and then treated with a single 100mg/kg dose of the
alkylating agent N-ethyl-S-nitrosourea (ENU). Pax5+/- mice exhibited a markedly
increased frequency of ALL in comparison to wild type animals with 24 of 25 Pax5+/animals succumbing to leukemia (median latency 246 days), compared to only 3 of 20
Pax5+/+ animals (P<0.0001, Figure 3-5). Furthermore, 20 of 22 evaluable Pax5+/- tumors
were of B-progenitor cell lineage, in contrast to the Pax5+/+ leukemias which were either
myeloid (N=2) or T-lymphoid (N=1). Taken together these data demonstrate that
haploinsufficiency of Pax5 results in an increased susceptibility to the development of B
progenitor acute lymphoblastic leukemia.
3.3.2 Mono-allelic Loss of Pax5 Cooperates with Arf Loss in BCR-ABL1
Induced ALL
In addition to PAX5 deletions, human BCR-ABL1 ALLs frequently harbor a
deletion of INK4A/ARF (CDKN2A), with over 20% of cases containing deletions of both
genes. Expression of BCR-ABL1 in primary murine pre-B cells induces the Arf
checkpoint and triggers an apoptotic response; thus, loss of Arf directly enhances the
oncogenicity of BCR-ABL1 to induce ALL in mice. To assess whether mono-allelic
deletions of Pax5 can cooperate with Arf loss in BCR-ABL1 induced leukemia, bone
marrow cells from mice heterozygous for null alleles of Pax5, Arf, or both genes were
transduced with MSCV-GFP-IRES-BCR-ABL1 and transplanted into recipient animals.
As shown in Figure 3-6, mice transplanted with BCR-ABL1 transduced Pax5+/- or Arf+/cells developed leukemias with a reduced latency when compared to wild type cells. No
significant difference was observed in the latency of disease onset between Pax5+/- and
Arf+/- cells. Transduction of bone marrow cells from compound heterozygous mice
(Pax5+/- Arf+/-) followed by transplantation into recipient mice resulted in a further
decrease in disease latency over that observed with wild type or single mutant cells
(Figure 3-6), thus demonstrating a direct cooperativity of these two lesions in the
development of BCR-ABL1-induced leukemia. Importantly, the immunophenotype of the
BCR-ABL1-induced leukemias were primarily dictated by the Pax5 gene status, with a
shift toward a more immature B cell phenotype with the loss of one Pax5 allele (Figure 33). Interestingly, in contrast to the clonal leukemias that developed in wild type or Pax5+/mice, Southern blot analysis of the Arf+/- leukemias revealed the majority to be
oligoclonal in nature (Figure 3-6; Figure 3-4).
3.3.3 Mutations of Pax5 and Ink4a/Arf are Spontaneously Selected For during
Leukemogenesis
Our data demonstrate that mono-allelic loss of Pax5 not only cooperates with
BCR-ABL1 in leukemogenesis, but further enhance the known cooperativity of Arf loss.
These data raise the possibility that BCR-ABL1-induced leukemias may spontaneously
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Figure 3-5 Kaplan-Meier survival curves of mice treated with ENU
Kaplan-Meier survival curve of mice that were injected with one dose of 100mg/kg ENU
(N-ethyl-S-nitrosourea). Twenty four of twenty five Pax5+/- animals succumbed to
disease with a median survival of 246 days while only three of twenty Pax5+/+ animals
developed leukemia (P<0.001). These data suggest that Pax5 haploinsufficiency
cooperates during leukemogenesis in multiple animal models.
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Figure 3-6 Pax5 and Ink4a/Arf haploinsufficiency cooperate with BCR-ABL1 to
induce ALL
A, Kaplan-Meier plot showing survival of mice transplanted with MSCV-GFP-IRESBCR-ABL1 transduced Pax5+/+, Pax5+/-, Arf+/- or Pax5+/- Arf+/- bone marrow cells
(p<0.0001). Pax5+/- and Arf+/- leukemias develop with a decreased latency when
compared to Pax5+/+ leukemias, p = 0.01 and p < 0.001, respectively. Pax5+/- and Arf+/tumors develop with no significant change in latency when compared to each other p =
0.077. Pax5+/- Arf+/- tumors develop with a decreased latency when compared to Pax5+/or Arf+/- tumors p = 0.007 and p = 0.0045, respectively. All p values calculated using
Breslow-Geahn-Wilcoxon test. N=10 in all experimental arms. B, Southern Blot Analysis
of HindIII digested genomic DNA from Arf+/- and Pax5+/- Arf+/- leukemias hybridized
with a 724bp GFP probe.
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select for mutations in these genes. Further supporting this possibility was the occurrence
of a Pre-Pro-B cell immunophenotype in a subset of Pax5+/- leukemias, and in rare wild
type and Arf+/- cases, suggesting that this immature phenotype may results from
additional lesions in B cell development genes. To explore these hypotheses, we
performed array-based comparative genomic hybridization (aCGH) on 50 BCR-ABL1induced leukemias (15 Pax5+/+, 25 Pax5+/-, and 10 Arf+/-) to identify regions of copy
number alterations (CNAs). For this analysis we used Agilent (Santa Clara, CA, USA)
murine oligonucleotide microarrays containing over 450,000 probes with a resolution
across the genome of approximately 4.5kb. To further enhance the resolution of this
platform, we customized the arrays by tiling at a 250 bp resolution through the 20 genes
that are most commonly mutated by CNAs in human BCR-ABL1 ALL. Included in this
list of genes are Ink4a/Arf, Pax5, Ebf1, and the Ikaros gene family Ikzf1, Ikzf2 and Ikzf3.
We also sequenced all coding exons of Pax5 in the leukemia cells from this cohort.
The aCGH data revealed a surprisingly low number of CNAs/leukemia with a
mean of only 0.96 CNAs/case (range 0-5), with losses (0.62, range 0-3) twice as common
as gains (0.34, range 0.3) (Table 3-2). The frequency of CNAs differed across the various
genotypes, with a mean of 1.73 CNAs/leukemia (range 0-5) in wild type mice compared
to only 0.60 and 0.70 in Pax5+/- and Arf+/- leukemias, respectively. Despite the paucity of
CNAs, a recurrent gain of chromosome 5 or 5q was identified in 7/15 BCR-ABL Pax5+/+
and 1/10 BCR-ABL1 Arf+/- leukemias, but never in BCR-ABL1 Pax5+/- leukemias (Figure
3-7A). In addition, a number of other recurrent lesions were identified, with the most
common abnormalities targeting Pax5, Ikzf3, and Ink4a/Arf (Figure 3-7; Figure 3-8;
Table 3-3).
Three leukemias (2 Pax5+/+ and 1 Pax5+/-) had focal deletions targeting the
Ink4a/Arf Ink4b locus, including a bi-allelic deletion in one of the Pax5+/+ leukemias that
included the entire Ink4a/Arf Ink4b locus (Figure 3-7B-C). The second Pax5+/+ leukemia
had a deletion that included the common exon of the Ink4a locus, exon 2, but did not
include Ink4b (Figure 3-7B-C). The Pax5+/- leukemia had a deletion that extended from
exon 1β through the end of Ink4b (Figure 3-7B-C). Taken together, the common region
of deletion in the three leukemias was Arf, thereby definitively identifying Arf as the
target of the mutations. Thus, loss of Ink4a/Arf is spontaneously selected for in BCRABL1-induced leukemia. To assess whether Arf was inactivated in the absence of
genomic alterations, we performed western blot analysis on protein lysates from a subset
of the leukemias and observed only a rare leukemia (two Pax5+/-) with markedly reduced
expression of p19ARF consistent with silencing. By contrast, expression of p19Arf was
detected in Arf+/- leukemias, consistent with haploinsufficiency.
The most common targets of CNAs in the murine leukemias were genes involved
in normal B cell development including Pax5, Ebf1, and Ikzf3 (Figure 3-8; Figure 3-9;
Table 3-3). In addition 4 leukemias were found to have point mutations of Pax5 effecting
conserved residues in the paired DNA-binding domain, or resulting in a frame-shift
mutation in the transcriptional regulatory domain (Figure 3-10; Table 3-4). Collectively,
mutations targeting these genes were identified in 30% of analyzed leukemias that arose
from Pax5+/+ or Arf+/- cells. Even more surprising was the identification of a high
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Table 3-2 Mean number of CNA in murine leukemias
Subtype
Pax5+/+
Pax5+/Arf+/All cases

N
15
25
10
50

Gains
(range)
0.93 (0-3)
0.04 (0-1)
0.20 (0-1)
0.34 (0-3)

Losses
(range)
0.80 (0-3)
0.56 (0-1)
0.50 (0-2)
0.62 (0-3)

Total
(range)
1.73 (0-5)
0.60 (0-2)
0.70 (0-2)
0.96 (0-5)

Figure 3-7 Detection of recurrent CNAs in murine BCR-ABL1 leukemias
A, Heatmap of log2 ratio of array CGH copy number data (median smoothed with a
window of five markers) for 50 murine BCR-ABL1 leukemias. The leukemias are
grouped according to their genotype (Pax5+/+, Pax5+/-, and Arf+/-) and the probes are
group by chromosomes as listed on the left. Blue depicts regions of loss and red regions
of gain with the relative scale shown in the lower right. B, Heatmap of log2 ratio of array
CGH copy number data of the region on chromosome 4 that contains Ink4a/Arf and Ink4b
for 3 BCR-ABL1 leukemias that have acquired CNAs involving this locus. C, Genomic
map of the Ink4a/Arf and Ink4b locus showing the location of the CGH oligonucleotide
probes (blue lines at the top) and the position of the individual genes contained within
this genomic region (bottom). * indicates a gap in the UCSC genome build. The log2 copy
number data for the three BCR-ABL1 leukemias are depicted. The red arrows indicate the
genomic location of exons analyzed by quantitative PCR for copy number validation.
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Figure 3-8 Pax5 is a common target of copy number alterations
A, Heatmap of log2 ratio of array CGH copy number data of the region on chromosome 4
that contains Pax5 for 2 BCR-ABL1 Pax5+/- leukemias that have acquired deletions of the
non-targeted, wild type Pax5 allele. B, Genomic map of the Pax5 locus showing the
location of the CGH oligonucleotide probes (blue lines at the top) and the position of the
gene contained within this genomic region (Bottom). The log2 ratio data for two BCRABL1 leukemias are depicted. The red arrows indicate the genomic location of the exons
analyzed by quantitative PCR for copy number validation. C, Heatmap of log2 ratio of
array CGH copy number data of the region containing Pax5 exon 2 (represented by a
single probe within this region). Pax5 exon 2 was deleted in the targeted Pax5 null allele.
A deletion involving the single exon 2 probe was detected in 7 Pax5+/- leukemias,
suggesting gene conversion leading to bi-allelic targeted alleles. D, Genotyping PCR
confirmed loss of the wild type allele in leukemias that had deleted the exon 2 probe
(designated by an *). Western blot analysis also demonstrated an absence of Pax5 protein
expression in these leukemias. WT, wild type band; KO, knock out band.
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Table 3-3 Recurring CNA (rank ordered by frequency)
Genes
Pax5*
Ikzf3
+5
Ink4a/Arf Ink4b
+12
+18

Loss/
Gain
Loss†
Both
Gain
Loss
Gain
Gain

Pax5+/+
N=15
2 (13%)
3 (20%)
7 (47%)
2 (13%)
1 (7%)
2 (13%)

Pax5+/- ‡
N=25
9 (36%)
3 (12%)
0
1 (4%)
0
0

Arf+/N=10
1 (10%)
3 (30%)
1 (10%)
0
1 (10%)
0

# total
lesions
12
10
8
3
2
2

*Includes loss of heterozygosity (LOH) in 7 Pax5+/- leukemias.
†Eleven of twelve CNA were deletions while one was amplification.
‡Pax5+/- leukemias reveal a significant increase in acquired Pax5 lesions, however, the
cohort has been biased by the selection of leukemias that harbor an immature
immunophenotype.

Figure 3-9 Ikzf3 copy number analysis
A, Log2 ratio aCGH copy number data of chromosome 11 flanking Ikzf3 exon 2 for 12
representative leukemias (9 with CNA and 3 without) showing deletion or amplification
of Ikzf3 exon 2. B, Coverage of the Ikzf3 locus for four of the leukemias shown in A.
Each vertical line represents the genomic position and log ratio of an individual marker.
A Red arrow indicates the genomic location of a quantitative PCR assay.
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Figure 3-10 Pax5 point mutations
A, Schematic of the functional domains of Pax5 showing the location of missense (▼)
and frameshift (♦) mutations detected in this study. The mutations in red correspond to
the most frequent Pax5 mutation detected in human pediatric ALLs. PD, paired domain,
O, octapeptide domain, H, homeodomain, TD, transactivating domain, A, activating, I,
inhibitory. B, Structural modeling of the position of the Pax5 paired domain mutations
and their relationship to DNA-binding and Ets protein interaction. The DNA double helix
is blue, the paired Pax5 DNA binding domain is yellow, and ETS-1, which binds to Pax5
resulting in an increase in the latter’s DNA-binding activity, is green. Pax5 mutations that
have been previously identified in human pediatric ALL are shown in red. Each mutation
is predicted to either disrupt DNA-binding or alter the transcriptional regulatory domains
of the protein.
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Table 3-4 Mutation analysis (including CNAs and re-sequencing of Pax5)
ID
100
102
116
120
124
128
228
136
140
144
148
152
156
188
192
176
184
172
180
230
234
238
242
246
250
254
258
262
266
104
106
160
164
168
196
200
204
208
212
216

Genotype
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/+
Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/Pax5+/-

IP*
Pre-B
Pre-B
Pre-pro B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pro-B
Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Mixed Pre-B/Pro-B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
Pre-pro B
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Pax5 Mutation† Other CNA

homo G85R
Arf deln
Ebf1 Δ6-7/+5

intron 5 deln

intron 5 amp

Arf deln/Ikzf3 deln/+5
+5
+5
Ikzf3 amp
+5/+18
+12
Ikzf3 deln/+5
Arf deln

P321fs
P80R
Ikzf3 deln
Ikzf3 deln

Ikzf3 deln

LOH
LOH
LOH
LOH
LOH
LOH
R38H
Δ1-6
Δ1-8
LOH

Table 3-4 continued
ID
270
274
278
282
286
290
294
298
302
306

Genotype
Arf+/Arf+/Arf+/Arf+/Arf+/Arf+/Arf+/Arf+/Arf+/Arf+/-

IP*
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B
Pre-B

Pax5 Mutation† Other CNA
+12

intron 5 deln

Ikzf3 deln
Ikzf3 deln
Ikzf3 deln

*IP, immunophenotype; LOH, loss of heterozygosity; Δ, deletion
†Pax5 mutations include deletions, amplification, LOH, and sequence mutations
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frequency of mutations (CNAs and point mutations) in the non-targeted Pax5 allele in
BCR-ABL1 Pax5+/- leukemias. Specifically, two Pax5+/- leukemias had focal deletions
affecting a subset of the Pax5 coding exons, three had Pax5 point mutations, and 7 had
undergone a gene conversion (copy neutral loss-of-heterozygosity) event leading to loss
of the wild type allele, duplication of the targeted Pax5 null allele, and an absence of
Pax5 expression (Figure 3-8C-D; Table 3-4). Thirteen of the Pax5+/- leukemias were
selected for genomic analysis because of a very immature Pro-B or Pre-Pro-B
immunophenotype. Remarkably, 12 of these 13 leukemias had mutations of the wild type
Pax5 allele. In addition, a single leukemia that arose in Pax5+/+ cells had a very immature
Pre-Pro-B cell immunophenotype and was found to have a homozygous G85R Pax5
DNA-binding domain mutation (Figure 3-10; Table 3-4). Thus, spontaneous inactivation
of the wild type Pax5 allele is selected for at a relatively high frequency and correlates
with a more immature phenotype. Taken together these data demonstrate a strong
selective pressure for the acquisition of loss of function mutations in genes that regulate
the normal transcriptional cascade required for early B cell differentiation.
3.3.4 Gene Expression Analysis Reveals Similarities between the Leukemias and
Their Normal Counterparts
Due to the importance of Pax5 during normal B-cell development, gene
expression profiling of flow sorted cells from distinct stages of B-cell development i.e.,
Hardy fractions A-F from Pax5+/+ and Pax5+/- mice were performed. In addition, to
investigate the effect of complete loss of Pax5 on the gene expression pattern during
early B-cell development, cells from Hardy fraction A and B, were flow sorted from
Pax5-/- mice. In our first analysis, we used principal component analysis (PCA) and
multi-group comparison to explore the gene expression changes that occur during normal
development. This analysis revealed that cells from the different Hardy Fractions have
distinct gene expression patterns (q =7.2 x 10-19) and the PCA accurately captures the
temporal changes that occur during normal differentiation (Figure 3-11A). This analysis
also showed that subtle gene expression changes occur with regard to a heterozygous loss
of Pax5. In Hardy fraction A, no difference in the gene expression pattern could be
detected with PCA or other supervised methods in bone marrow cells obtained from
Pax5+/+, Pax5+/-, or Pax5-/- mice. As expected, in Hardy fraction B, both PCA and
supervised analyses revealed that BM from Pax5-/- mice has a distinct gene expression
profile. However, the difference that could be seen between Pax5+/+ and Pax5+/- cells was
very subtle using this algorithm.
Next, we investigated the relationship between normal flow sorted B-cells and the
leukemias from Pax5+/+, Pax5+/-, and Pax5+/- mice that later lost their second Pax5 allele.
PCA showed that all leukemias, irrespective of their Pax5 status, were distinct from their
normal counterparts (Figure 3-11B). To investigate if the leukemias shared more subtle
transcriptional programs with any of the normal Hardy fractions, we applied PCA
obtained from the normal cells only (Figure 3-11) on the leukemias. In this analysis, the
leukemias do not contribute to the principal components, allowing us to investigate the
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Figure 3-11 Gene expression analysis
A, Principal Component Analysis of Hardy fraction development on Hardy stages A-F.
All three Pax5 genotypes are included. L, leukemias; L-/-, Pax5-/- leukemias; B-/-, Pax5-/Hardy fraction B. B, PCA of Hardy fractions and Pax5 leukemias reveals that leukemias
harbor a gene expression profile that is unique when compared to normal B-cells. C, The
PCA analysis from part A was locked and the leukemias were overlaid in order to
determine which Hardy stage of B-cell development the leukemias most closely
resemble. This analysis revealed that the Pax5+/+ leukemias most closely resemble Hardy
fraction C. The leukemias that have lost one Pax5 allele are most similar to Hardy
fraction B, while the leukemias that have lost both functional Pax5 alleles, L-/-, most
closely resemble Hardy fraction B cells from Pax5-/- animals, depicted here as B-/-. D,
The top 100 genes that define Hardy Fractions A through F are represented along with 20
mouse leukemias (10 Pax5+/+ and 5 Pax5+/- and 5 Pax5+/- that have undergone LOH and
are effectively Pax5-/-). These gene expression profiles reveal that the Pax5 leukemias
harbor gene expression profiles that are relatively immature; sharing the most similarity
with the gene expression profile of Hardy fractions B and C. E, Gene expression analysis
assessing changes that occur in Hardy fraction B when Pax5 is lost. Pax5-/- Hardy
fraction B cells harbor a completely dysregulated gene expression profile when compared
to wild-type Hardy fraction B cells. Several dysregulated Pax5 targets are included in the
top 100 genes that define Hardy fraction B, including Rag2, Lef1, and CD19.
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similarities between the normal and the malignant cells (Figure 3-11C). This analysis
showed that most of the leukemias shared transcriptional programs with Hardy fraction B
cells. Interestingly, as can clearly be seen in Figure 3-11C, leukemias developed in
Pax5+/- mice that, as demonstrated by ArrayCGH had lost their other Pax5 allele,
clustered close to the Hardy fraction B cells from Pax5-/- mice. In addition, several of the
leukemias that developed in Pax5+/+ mice shared transcriptional programs with Hardy
fraction C cells suggesting that loss of one Pax5 allele is enough to impair leukemia
development past Hardy fraction B.
To further explore the similarities between normal B-cells and the leukemias, the
top 100 uniquely expressed genes in Hardy fractions A-F were extracted and investigated
in the murine leukemias (Figure 3-11D). This analysis showed, as above, that the
leukemias share the expression of some genes with Hardy fractions B and C.
Collectively; the above analyses indicate that the murine leukemias maintain the
transcription of certain genes that are important during the normal differentiation, likely
reflecting the cell of origin of the leukemia. In addition, leukemias from Pax5+/- mice that
lost their second Pax5 allele during leukemia progression appear to reactivate genes that
normally are expressed in early B-cells, in agreement with their immature
immunophenotype. Importantly, although the leukemias maintain the activation of some
genes that are expressed during normal differentiation, they exhibit profoundly different
gene expression patterns as compared to their normal counterparts. Interestingly, N-Myc
is the top differentially expressed gene between the leukemias and normal cells.
Importantly, 10 wild-type and 10 Pax5 heterozygous leukemias were analyzed and half of
the Pax5 hets were selected because of their immature immunophenotype. Thus, it is
important to consider that the Pax5 het group is not representative of the majority of
Pax5 heterozygous leukemias.
3.3.5 Gene Set Enrichment Analysis Reveals Murine Ph+ Leukemias Harbor Stem
Cell-like Gene Expression Profile and Significantly Resemble Human Ph+ ALL
Our gene expression data demonstrate that as BCR-ABL1 leukemias lose a Pax5
allele, the leukemia becomes more immature and consequently harbors a gene expression
profile most similar to Hardy fraction B. In addition, the majority of B-progenitor ALLs
arrested at a stage of development very similar to Hardy fraction B. Taken together these
data suggest that further characterization of Hardy fraction B cells may yield valuable
insight into the mechanism by which Pax5 haploinsufficiency cooperates during BCRABL1 induced leukemogenesis.
In an effort to better understand the gene expression program in BCR-ABL1
leukemia cells we performed Gene Set Enrichment Analysis (GSEA). GSEA is a
statistical algorithm that is used to interrogate a defined gene expression for the common
expression of a set of a priori identified genes. We first generated a rank ordered gene list
by comparing the gene expression profiles of our murine BCR-ABL1 leukemias versus all
normal B-cell fractions. Next, we walked along our rank ordered gene list with a series
of currated genesets from the Molecular Signatures Database. Our GSEA revealed that
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the core ESC-like geneset82 was significantly enriched in our murine BCR-ABL1
leukemias (FDR=0.0869; Figure 3-12A). The core ESC-like gene set is a set of genes that
are commonly expressed in both murine and human embryonic stem cells. This geneset
is comprised of 335 genes many of which are regulated by C-Myc. Interestingly, the
gene with the highest expression in our leukemias was N-Myc. Taken together these data
suggest that our BCR-ABL1 leukemias harbor a gene expression signature that is similar
embryonic stem cells. Furthermore, our leukemias reveal high expression of N-Myc
which may explain the similarities in expression. Next we performed GSEA on normal
B-cells by comparing Hardy fraction A to all others and B to all others, for all Hardy
fractions. We then assessed the enrichment of the core ESC-like geneset in any of the
Hardy fractions. This GSEA revealed that the core ESC-like geneset was only
significantly enriched in Hardy fraction B. Taken together, these data suggest that the
stem cell signature identified in the leukemias results from an inherent signature retained
by Hardy fraction B cells and further suggests that Pax5 loss may function to arrest B-cell
development in such a way that the cell becomes more stem cell like.
We next used GSEA to explore similarities between human and mouse BCRABL1 ALLs. We generated a rank ordered gene list by comparing the gene expression
profiles of human BCR-ABL1 ALL to all other B-progenitor ALL subtypes. Next, we
generated a murine BCR-ABL1 geneset by taking the top 100 genes that are expressed
highly in our murine leukemias. Subsequently, we found that the top 100 genes from our
murine BCR-ABL1 leukemias were significantly enriched in human BCR-ABL1 ALLs
suggesting that our murine model of BCR-ABL1 ALL is accurately recapitulating the
human malignancy (FDR=0.161; Figure 3-12B).
3.4 DISCUSSION
In summary, we have shown that Pax5 haploinsufficiency cooperates with BCRABL1 during leukemogenesis. We observed that Pax5+/- BCR-ABL1 leukemias exhibit a
more immature immunophenotype when compared to wild-type leukemias, including
19% which harbored a Pre-pro B-cell immunophenotype. Furthermore, we observed that
our murine BCR-ABL1 leukemias acquire many of the same cooperating oncogenic
lesions that are seen in human Ph+ ALLs, including recurrent copy number alterations of
Pax5, Ink4a/Arf, and Pax5 sequence mutations. We have also shown that Arf
haploinsufficiency further cooperates with Pax5 haploinsufficiency during BCR-ABL1
induced leukemogenesis suggesting that these two pathways may further cooperate
during leukemogenesis. Importantly, in leukemias that started as Arf+/-, we were able to
show that these leukemias continue to express Arf protein suggesting that the wild-type
Arf allele is intact and Arf is functioning as a haploinsufficient tumor suppressor.
However, there is the possibility that Pax5 loss may somehow impact the Arf/Mdm2/p53
tumor suppressor pathway and may act as a second hit in this pathway, thereby
eliminating the need to inactivate the wild-type Arf allele. Future studies assessing the
interplay between Pax5 status and Arf expression will need to be performed.
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Figure 3-12 Gene set enrichment analysis
A, Gene Set Enrichment Analysis (GSEA) was used to evaluate enrichment of a host of
genesets in murine BCR-ABL1 leukemias. A rank ordered gene list was generated by
comparing murine BCR-ABL1 ALLs with normal Hardy fraction B cells (A-F). GSEA
was then performed and revealed that the geneset “Core-ESC-like module” was
significantly enriched in the leukemias (FDR=0.0869), suggesting that the murine BCRABL1 leukemias share similar expression of core embryonic stem cell genes. B, Gene Set
Enrichment Analysis (GSEA) reveals that the top 100 overexpressed genes from Pax5+/+
leukemias enrich in BCR-ABL1 signature of human B-ALL. A rank ordered gene list was
generated by comparing BCR-ABL1 ALLs with other B-lymphoid ALLs to define the
BCR-ABL1 signature. GSEA was then performed and the top 100 overexpressed genes
from the Pax5+/+ leukemias were found to be enriched in the human BCR-ABL1 signature
(FDR=0.161).
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In an effort to gain mechanistic insight into the contribution that Pax5 loss may
play during leukemogenesis we performed gene expression analysis and compared the
expression profiles of Ph+ leukemias to their normal counterparts. Preliminary supervised
gene expression analysis revealed that normal Hardy fraction stages of B-cell
development harbor unique gene expression profiles. Furthermore, our leukemias
seemed to most closely resemble Hardy fraction B and C. A more sophisticated principal
component analysis revealed that each stage of B-cell development has an identifiable,
unique transcriptional program that differs from all other stages of B-cell development.
We also observed that in comparison to normal B-cells, B-progenitor leukemias harbor a
significantly different gene expression signature. However, when we perform principal
component analysis on normal B-cells and “lock” the analysis, and then add the
leukemias onto this analysis we see that wild-type BCR-ABL1 leukemias are most similar
to Hardy fractions B and C. Interestingly, when one Pax5 allele is lost, all the leukemias
now are most similar to Hardy fraction B suggesting that Pax5 haploinsufficiency
contributes to a block in B-cell development. Furthermore, gene set enrichment analysis
revealed that a geneset comprised of 335 genes that are commonly expressed in murine
and human embryonic stem cells is enriched in our murine BCR-ABL1 leukemias
suggesting that our leukemias harbor a stem cell like gene expression profile.
Interestingly, when we compare each Hardy fraction versus all other normal B-cells we
see that the core embryonic stem cell-like geneset is only enriched in Hardy fraction B
suggesting that Hardy fraction B cells harbor a latent stem cell like gene expression
signature. Interestingly, Pax5 is first expressed in Hardy fraction B and is absolutely
necessary for B-cell commitment and development.8,18 In the absence of Pax5, B-cells
are arrested at Hardy stage B and in the context of appropriate growth factors can
dedifferentiate into many other hematopoietic lineages.18 Taken together, our data
suggests that Hardy fraction B cells have a latent embryonic stem cell-like gene
expression signature and that loss of Pax5 during leukemogenesis provides a block in Bcell development at Hardy fraction B providing the developing leukemia with a more
stem cell-like environment. It is very likely that Hardy fraction B cells are the last
progenitor stage in the B-cell lineage and wild-type Pax5 expression is absolutely critical
to commit B-cells to differentiate. Pax5 is in this context a haploinsufficient tumor
suppressor. Pax5 haploinsufficiency not only cooperates with BCR-ABL1 but also with
other oncogenic lesions, like ENU, suggesting that its role as a haploinsufficient tumor
suppressor is not limited to collaborating with the very strong BCR-ABL1 oncogene.
Taken together, these data suggest that the lesions that have been identified by
SNP analysis in human ALLs are cooperating oncogenic lesions and further examination
of the pathways involved may yield important insights into future therapeutic avenues
worth exploration in the global effort to cure ALL.
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CHAPTER 4
BCR-ABL1 LYMPHOBLASTIC LEUKEMIA IS CHARACTERIZED BY THE
DELETION OF IKAROS
4.1 INTRODUCTION
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of
disorders characterized by recurring chromosomal abnormalities including translocations,
trisomies and deletions. An ALL subtype with especially poor prognosis is characterized
by the presence of the Philadelphia chromosome arising from the t(9;22)(q34;q11.2)
translocation, which encodes the constitutively activated BCR-ABL1 tyrosine kinase.
BCR-ABL1 positive ALL constitutes 5% of paediatric B-progenitor ALL and
approximately 40% of adult ALL.21,22 Expression of BCR-ABL1 is also the pathologic
lesion underlying chronic myelogenous leukemia (CML).20 Data from murine studies
demonstrates that expression of BCR-ABL1 in hematopoietic stem cells can alone induce
a CML-like myeloproliferative disease, but cooperating oncogenic lesions are required
for the generation of a blastic leukemia.75,83 Although the p210 and p190 BCR-ABL1
fusions are most commonly found in CML and paediatric BCR-ABL1 ALL respectively,
either fusion may be found in adult BCR-ABL1 ALL.84 Importantly, a number of genetic
lesions including additional cytogenetic aberrations and mutations in tumour suppressor
genes have been described in CML cases progressing to blast crisis.85 However, the
specific lesions responsible for the generation of BCR-ABL1ALL and blastic
transformation of CML remain incompletely understood.85 To identify cooperating
oncogenic lesions in ALL, we recently performed a genome-wide analysis of paediatric
ALL.76 This analysis identified an average of 6.8 genomic copy number alterations
(CNA) in 9 BCR-ABL1 ALL cases, including deletions in genes that play a regulatory
role in normal B cell development.
4.2 MATERIALS AND METHODS
4.2.1 Patients and Samples
Two hundred eighty two patients with acute lymphoblastic leukemia (ALL)
treated at St. Jude Children’s Research Hospital, 22 adult BCR-ABL1 ALL patients
treated at the University of Chicago, and 49 samples obtained from 23 adult patients with
chronic myeloid leukaemia (CML) treated at the Institute of Medical and Veterinary
Science, Adelaide. The CML cohort included 24 chronic phase, 7 accelerated phase and
15 blast crisis samples, and three samples obtained at complete cytogenetic response. All
blast crisis samples were flow sorted to at least 90% blast purity prior to DNA extraction
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characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).19

65

using FACSVantage SE (with DiVa option) flow cytometers (BD Biosciences, San Jose,
CA) and fluorescein isothiocyanate labeled CD45, allophycocyanin labeled CD33 and
phycoerythrin labeled CD19 and CD13 antibodies (BD Biosciences). Germline tissue
was obtained by also sorting the non-blast population in 7 cases. Informed consent for the
use of leukemic cells for research was obtained from patients, parents or guardians in
accordance with the Declaration of Helsinki, and study approval was obtained from the
SJCRH institutional review board.
4.2.2 Cell Lines Examined by SNP Array
Thirty-six acute myeloid and lymphoid leukemia cell lines were genotyped using
the Affymetrix Mapping 250k Sty and Nsp arrays. These were the ALL cell lines 380
(MYC-IGH and BCL2-IGH B-precursor), 697 (TCF3-PBX1), AT1 (ETV6-RUNX1),
BV173 (CML in lymphoid blast crisis), CCRF-CEM (TAL-SIL), Jurkat (T-ALL),
Kasumi-2 (TCF3-PBX1), MHH-CALL-2 (hyperdiploid B-precursor ALL), MHH-CALL3 (TCF3-PBX1), MOLT3 (T-ALL), MOLT4 (T-ALL), NALM-6 (B-precursor ALL),
OP1 (BCR-ABL1), Reh (ETV6-RUNX1), RS4;11 (MLL-AF4), SD1 (BCR-ABL1), SUPB15 (BCR-ABL1), TOM-1 (BCR-ABL1), U-937 (PICALM-AF10), UOCB1 (TCF3-HLF),
YT (NK leukaemia); and the AML cell lines CMK (FAB M7), HL-60 (FAB M2), K-562
(CML in myeloid blast crisis), Kasumi-1 (RUNX1-RUNX1T1), KG-1 (myelocytic
leukaemia), ME-1 (CBFB-MYH11), ML-2 (MLL-AF6), M-07e (FAB M7), Mono Mac 6
(MLL-AF9), MV4-11 (MLL-AF4), NB4 (PML-RARA), NOMO-1 (MLL-AF9), PL21
(FAB M3), SKNO-1 (RUNX1-RUNX1T1) and THP-1 (FAB M5). Cell lines were
obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen,
Braunschweig, Germany; the American Type Culture Collection, Manassas, VA, from
local institutional repositories, or were gifts from Olaf Heidenreich (SKNO-1) and Dario
Campana (OP1). Cells were culture in accordance with previously published
recommendations.86 The paediatric BCR-ABL1 B-precursor ALL cell line OP187 was
cultured in RPMI-1640 containing 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM
glutamine and 10% fetal bovine serum. DNA was extracted from 5x106 cells obtained
during log phase growth after washing in PBS using the QIamp DNA blood mini kit
(Qiagen, Valencia, CA).
4.2.3 Single Nucleotide Polymorphism Microarray Analysis
Collection and processing of diagnostic and remission bone marrow and
peripheral blood samples for Affymetrix single nucleotide polymorphism microarray
analysis has been previously reported in detail.76 Affymetrix 250K Sty and Nsp arrays
were performed on all samples. 50k Hind 240 and 50k Xba 240 arrays were performed
for 252 ALL samples. SNP array CEL and SNP call TXT files (generated by Affymetrix
GTYPE 4.0 using the DM algorithm) have been deposited in NCBIs Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession numbers GSE9109-9113.
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4.2.4 Fluorescence In Situ Hybridization
Fluorescence in situ hybridization for IKZF1 deletion was performed using
diagnostic bone marrow or peripheral blood leukaemic cells in Carnoy’s fixative as
previously described.76 BAC clones CTD-2382L6 and CTC-791O3 (for IKZF1, Open
Biosystems, Huntsville, AL) were labeled with fluorescein isothiocyanate, and control
7q31 probes RP11-460K21 (Children’s Hospital Oakland Research Institute, Oakland,
CA) and CTB-133K23 (Open Biosystems), were labeled with rhodamine. At least 100
interphase nuclei were scored per case.
4.2.5 IKZF1 PCR, Cloning, Quantitative PCR and Genomic Sequencing
RNA was extracted and reverse transcribed using random hexamer primers and
Superscript III (Invitrogen, Carlsbad, CA) as previously described.76 IKZF1 transcripts
were amplified from cDNA using the Advantage 2 PCR enzyme (Clontech, Mountain
View) as previously described76 using primers that anneal in exon 0 and 7 of IKZF1. PCR
products were purified, and sequenced directly and after cloning into pGEM-T-Easy
(Promega, Madison, WI). Genomic quantitative PCR for exons 1-7 of IKZF1, and realtime PCR to quantify expression of Ik6 were performed as previously described.76 All
primers and probes are listed in Supplementary Table 3. Genomic sequencing of IKZF1
exons 0-7 in all ALL and CML samples was performed as previously described.76
4.2.6 Western Blotting
Whole cell lysates of 3-6x106 leukemic cells were prepared and blotted as
previously described76 using N- and C-terminus specific rabbit polyclonal Ikaros
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
4.2.7 Methylation Analysis
Methylation status of the IKZF1 promoter CpG island (chr7:50121508-50121714)
was performed using MALDI-TOF mass spectrometry of PCR-amplified, bisulfite
modified genomic DNA extracted from leukemic cells as previously described.49,76
4.2.8 Statistical Analysis
Associations between ALL subtype and IKZF1 deletion frequency were
calculated using the exact likelihood ratio test. Differences in Ik6 expression between
IKZF1 3-6 and non-3-6 cases was assessed using the exact Wilcoxon-Mann-Whitney
test. All P values reported are two-sided. Analyses were performed using StatXact v8.0.0
(Cytel, Cambridge, MA).
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4.3 RESULTS
4.3.1 Ikaros is Commonly Deleted in BCR-ABL1 ALL
To extend this analysis and identify lesions that distinguish CML from BCRABL1 ALL, we have now examined DNA from leukemic samples from 304 pediatric and
adult ALLs (254 B-progenitor, 50 T-lineage), including 21 pediatric and 22 adult BCRABL1 ALL, and 23 adult CML cases. Samples were analyzed using the 250k Sty and Nsp
Affymetrix SNP arrays (and also the 100K arrays for most cases). This identified a mean
of 8.79 somatic CNA per BCR-ABL1 ALL case (range 1-26), with 1.44 gains (range 013) and 7.33 losses (range 0-25). No significant differences were noted in the frequency
of CNAs between paediatric and adult BCR-ABL1 ALL cases. The most frequent somatic
CNA was deletion of IKZF1, which encodes the transcription factor Ikaros (Table 4-1).
IKZF1 was deleted in 36 (83.7%) of 43 BCR-ABL1 ALL cases, including 76.2% of
paediatric and 90.9% of adult BCR-ABL1 ALL cases. CDKN2A was deleted in 53.5% of
BCR-ABL1 ALL cases, most of which (87.5%) also had deletions of IKZF1 (Table 4-1).
Conversely, of the BCR-ABL1 ALL cases with IKZF1 deletions, 41.6% lacked CDKN2A
alterations. Deletion of PAX5 occurred in 51% of BCR-ABL ALL cases, again with the
majority also having a deletion of IKZF1 (95%) (Table 4-1). No other defining CNAs
were identified in the rare BCR-ABL1 ALL cases that lacked a deletion of IKZF1.
Ikaros is a member of a family of zinc finger nuclear proteins that is required for
normal lymphoid development.88-91 Ikaros has a central DNA-binding domain consisting
of four zinc fingers, and a homo- and heterodimerization domain consisting of the two Cterminal zinc fingers92 (Figure 4-1A). Alternative splicing generates multiple Ikaros
isoforms, several of which lack the N-terminal zinc fingers required for DNA binding;
however, the physiological relevance of these isoforms in normal hematopoiesis remains
unclear.88-90,93 The IKZF1 deletions identified in BCR-ABL1 ALL were predominantly
mono-allelic and were limited to the gene in 25 cases, conclusively identifying IKZF1 as
the genetic target (Figure 4-1B). In 19 cases the deletions were confined to a subset of
internal IKZF1 exons, most commonly exons 3-6 (3-6; N=15). Importantly, the ∆3-6
deletion is predicted to encode an Ikaros isoform that lacks the DNA-binding domain but
retains the C-terminal zinc fingers. The IKZF1 deletions were confirmed by FISH and
genomic quantitative PCR, and were in the predominant leukemic clone. Detailed
analysis failed to reveal any evidence of either IKZF1 point mutations or inactivation of
its promoter by CpG methylation in primary ALL samples.
4.3.2 Ikaros Deletions Result in the Expression of a Dominant Negative Isoform Ik6
The expression of aberrant, dominant negative Ikaros isoforms in B- and Tlineage ALL has been previously reported by several groups,94-101 although alternative
splicing has been reported to be the underlying mechanism.102 Importantly, the ∆3-6
isoform of Ikaros has been shown to function as a dominant negative inhibitor of the
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Table 4-1 Frequency of recurring DNA copy number abnormalities in ALL
ALL subtype (N)
B-progenitor (254)
BCR-ABL1 (43)
- childhood (21)
- adult (22)
Hypodiploid (10)
Other B-ALL (75)
High hyperdiploid (39)
MLL-rearranged (22)
TCF3-PBX1 (17)
ETV6-RUNX1 (48)
T-lineage (50)
Total (304)
P

IKZF1

CDKN2A

PAX5

C20orf94

RB1

MEF2C

EBF1

BTG1

DLEU

FHIT

ETV6

36
16
20
5
15
2
1
0
0
2
61
6.6x10-27

23
13
10
10
25
8
4
6
14
36
126
7.4x10-10

22
12
10
10
22
4
4
7
16
5
90
1.4x10-9

10
3
7
0
4
1
0
0
6
1
22
7.0x10-8

8
4
4
0
1
3
2
2
2
6
24
1.1x10-6

6
4
2
0
0
0
0
0
0
1
7
0.0004

6
3
3
1
2
0
0
0
5
3
17
0.0247

6
2
4
1
5
0
0
0
7
0
19
1.5x10-7

4
3
1
0
1
5
3
2
4
3
22
2.6x10-6

4
2
2
1
3
0
0
0
6
0
14
0.0076

3
1
2
2
10
3
2
0
33
4
57
9.1x10-15

The prevalence of recurring genomic abnormalities in BCR-ABL1 B-progenitor ALL identified by SNP array analysis is shown for
each ALL subtype. The exact likelihood ratio P value for variation in the frequency of each lesion across ALL subtypes is shown. The
DLEU region at 13q14 incorporates the miRNA genes MIRN16-1 and MIRN15A.
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Figure 4-1 IKZF1 deletions in BCR-ABL1 ALL
A, Domain structure of IKZF1. Exons 3-5 encode four N-terminal zinc fingers (black
boxes) responsible for DNA binding. The C-terminal zinc fingers encoded by exon 7 are
essential for homo- and heterodimerization. B, Genomic organization of IKZF1 and
location of each of the 36 deletions observed in BCR-ABL1 B-progenitor ALL. Each line
depicts the deletion(s) observed in each case. In five cases, two discontiguous deletions
were observed. Hemizygous deletions are solid lines and homozygous deletions dashed.
Arrows indicated deletions extending beyond the limits of the figure. The exact
boundaries of the deletions were defined by genomic qPCR, and for IKZF1 3-6, by
long-range genomic PCR (red arrow). C, dChipSNP raw log2 ratio copy number data
depicting IKZF1 deletions for 29 BCR-ABL1 cases and 3 B-progenitor ALL cell lines.
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transcriptional activity of Ikaros and related family members.92 Moreover, mice
homozygous for either an Ikzf1 null mutation103 or a dominant negative Ikzf1 mutation67
exhibit profound defects in lymphoid development, and mice heterozygous for a
dominant negative Ikzf1 mutation develop clonal T cell expansions and
lymphoproliferative diseases,69 demonstrating that alteration in the level of Ikzf1
expression is oncogenic.
The high frequency of focal deletions in IKZF1 in BCR-ABL1 ALL suggests that
expression of alternative IKZF1 transcripts may be the result of specific genetic lesions,
and not alternative splicing of an intact gene. To further explore this possibility, we
performed RT-PCR analysis for IKZF1 transcripts in 159 cases (Figure 4-2). This
demonstrated that expression of the Ik6 transcript, which lacks exons 3-6, was
exclusively observed in cases harboring the IKZF1 3-6 deletion (Figure 4-2B).
Furthermore, we detected two novel Ikaros isoforms exclusively in cases with larger
deletions; Ik9 in a case with deletion of exons 2-6, and Ik10 in three cases with deletion
of exons 1-6 (Figure 4-2A-B). For each isoform, Ik6, 9 and 10, there was concordance
between the transcripts detected by RT-PCR and the extent of deletion defined by SNP
array and genomic PCR analysis (Figure 4-2B). Moreover, analysis of 22 IKZF1 3-6
and 29 non-3-6 cases with a quantitative PCR assay specific for the Ik6 transcript
confirmed that Ik6 expression was restricted to cases with the 3-6 deletion (P=6.41x1015
). In addition, the Ik6 protein isoform was only detectable by western blotting in cases
with a 3-6 IKZF1 deletion (Figure 4-2C). We also did not observe expression of Ik6
following the enforced expression of BCR-ABL1 in Arf null or wild type murine
hematopoietic precursors. Together, these data indicate that the expression of non-DNA
binding Ikaros isoforms is due to IKZF1 genomic abnormalities, and not aberrant posttranscriptional splicing induced by BCR-ABL1, as has been suggested.102
4.3.3 Deletion of Ikaros is an Important Event in the Transformation of CML to
Lymphoid Blast Crisis
To identify CNAs in CML, we performed SNP array analysis on 23 CML cases.
In addition to chronic phase CML (CP-CML), we also examined matched accelerated
phase (AP-CML, N=7) and blast crisis (BC-CML, N=15, 12 myeloid and 3 lymphoid)
samples. This identified only 0.47 CNAs per CP-CML case (range 0-8), suggesting that
BCR-ABL1 is sufficient to induce CML, but alone does not result in substantial genomic
instability. Importantly, no recurrent lesions were identified. In contrast, there was a
mean of 7.8 CNAs per BC-CML case (range 0-28), with IKZF1 deletions in four BC
samples, including two of the three cases with lymphoid blast crisis (Figure 4-3A). Two
of the IKZF1 deletions involved the entire gene (CML-#4-BC and #22-BC), one 3-6
(CML-#1-BC, which was associated with Ik6 expression by RT-PCR) and one 3-7
(CML-#7-BC). CML-#7-BC also had an IKZF1 nonsense mutation in the C-terminal zinc
finger domain of exon 7 in the non-deleted allele (c.1520C>A, p.Ser507X, Figure 4-3B).
One BC sample had a CDKN2A deletion, and four cases had CNAs involving PAX5 (two
deletions, one internal amplification, one trisomy 9), with two of these also having IKZF1
deletion. CNAs were identified in two AP-CML samples.
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Figure 4-2 Ikaros isoforms in ALL blasts
A, Domain structure of the IKZF1 isoforms detected by RT-PCR, examples of which are
shown in panel B. B, RT-PCR for IKZF1 transcripts (using exon 0 and 7 specific
primers) in representative cases with various IKZF1 genomic abnormalities. Each case
expressing an aberrant isoform had a corresponding IKZF1 genomic deletion. IKZF1 36 was also detected in the BCR-ABL1 ALL cell lines SUP-B15 and OP1, and 1-6 in the
ALL cell line 380. C, Western blotting for Ikaros using a C-terminus specific polyclonal
antibody. Ik6 was only detectable in cases with IKZF13-6. The 1-6 and 2-6 deletions
do not produce a detectable protein. In three cases with multiple focal hemizygous
deletions involving different regions of IKZF1 (BCR-ABL-SNP-#26, -#29, and -#31), no
wild type Ikaros was detectable by RT-PCR or western blotting, indicating that the
deletions involve both copies of IKZF1 in each case.
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Figure 4-3 IKZF1 deletions in blast crisis CML
A, dChipSNP log2ratio copy number heatmaps of four CML cases showing acquisition of
IKZF1 deletions at progression to blast crisis. B-C, Pherograms of IKZF1 exon 7
sequencing demonstrating acquisition of the c.1520C>A, p.Ser507X mutation at blast
crisis in case CML-#7. As this case has a concomitant hemizygous IKZF1 deletion
involving exon 7, the mutation appears homozygous.
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These data demonstrate an increased burden of genomic aberrations during
progression of CML, with IKZF1 mutation a frequent event in the transformation of CML
to lymphoid blast crisis.
4.3.4 Ikaros Deletions are Likely a Result of Aberrant RAG Activity
To explore the mechanism responsible for the identified IKZF1 deletion, we
sequenced the IKZF1 3-6 genomic breakpoints. The deletions were restricted to highly
localized sequences in introns 2 and 6. Moreover, heptamer recombination signal
sequences (RSSs) recognized by the RAG enzymes during V(D)J recombination104 were
located immediately internal to the deletion breakpoints, and a variable number of
additional nucleotides were present between the consensus intron 2 and 6 sequences,
suggestive of the action of terminal deoxynucleotidyl transferase (TdT). Together, these
data suggest that the IKZF1 3-6 deletion arises due to aberrant RAG-mediated
recombination.
4.4 DISCUSSION
In summary, we have identified a high frequency of CNAs in BCR-ABL1 ALL
and BC-CML, but not in CP-CML. We observed a near obligate deletion of IKZF1 in
BCR-ABL1 ALL, with 83.7% of paediatric and adult cases containing deletions that lead
to a reduction in dose and/or the expression of an altered Ikaros isoform. By contrast,
deletion of IKZF1 was not detected in CP-CML, but was identified as an acquired lesion
in 2 of 3 lymphoid BC-CML samples. These data, together with the low frequency of
IKZF1 deletions in other pediatric B-progenitor ALL cases, and the lack of focal IKZF1
aberrations in recently reported genomic analysis of non-hematopoietic tumors105 suggest
that alterations in Ikaros directly contribute to the pathogenesis of BCR-ABL1 ALL. How
reduced activity of Ikaros, and possibly that of other family members through the
expression of dominant negative Ikaros isoforms, collaborates with BCR-ABL1 to induce
lymphoblastic leukemia remains to be determined. Importantly, mice with attenuated
Ikaros expression exhibit a partial block of B lymphoid maturation at the pro-B cell
stage,106 suggesting that Ikaros loss may contribute to the arrested B lymphoid maturation
in BCR-ABL1 ALL. However, the high co-occurrence of PAX5 deletions in many cases
suggests that IKZF1 deletion contributes to transformation in additional ways. The
frequent co-deletion of CDKN2A (encoding INK4A/ARF) with IKZF1 in BCR-ABL1
ALL is a notable finding. This suggests that attenuated Ikaros activity may either
collaborate with disruption of INK4A/ARF-mediated tumor suppression, or act through
alternative uncharacterized tumor suppressor pathways in ALL. Furthermore, the
identification of aberrant RAG-mediated recombination as the mechanism underlying
deletions of IKZF1 suggests that the cellular target of this transforming event is
downstream of the hematopoietic stem cell. Dissecting the contribution of altered Ikaros
activity to BCR-ABL1 leukaemogenesis should not only provide valuable mechanistic
insights, but will also help to determine if the presence of this genetic lesion can be used
to gain a therapeutic advantage against this aggressive leukemia.
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CHAPTER 5
OVERALL SUMMARY AND FUTURE DIRECTIONS
Significant progress has been made in the treatment of ALL with cure rates
approaching 90%. Despite the significant advances in the treatment of children with
ALL, 10% of children do not survive and many children endure significant complications
associated with current therapy. As a result, it is critical that the full complement of
genetic mutations within ALL be identified so that therapy can be adjusted and improved
in order to cure every child and to minimize therapy related complications as much as
possible.
ALL is comprised of several distinct subtypes and in the majority of subtypes, the
initiator or driver lesion is known. In order to identify additional cooperating oncogenic
mutations we have performed genome-wide SNP analysis on nearly 250 ALL cases. The
SNP analysis revealed that genes that are responsible for B-cell development and
differentiation are mutated in 40% of B-progenitor ALLs. These mutations include
deletions, amplifications, translocations, and point mutations. The most common target
of mutation was the PAX5 gene which was found to be mutated in 32% of cases. As
discussed in chapter 2, there were several PAX5 mutations identified, the majority of
which resulted in either hemizygous loss of the gene or in the production of a
hypomorphic allele suggesting that PAX5 haploinsufficiency may be a cooperating lesion
during leukemogenesis. This result raises several questions for future study that have not
been addressed in this dissertation. We can clearly appreciate that PAX5 mutations are
common in ALL but what are the effects that PAX5 mutations have on the normal
function of the PAX5 protein? Chapter 3 discusses work that has been done elucidating
the finding that Pax5 haploinsufficiency cooperates with BCR-ABL1 during
leukemogenesis. However, there are additional mechanisms of PAX5 mutation in
addition to hemizygous loss, including point mutation, internal truncation, and
translocation. It will be important to understand the effects that these PAX5 mutations
have on normal PAX5 function.
In order to determine the effects that these mutations have on normal PAX5
function we will need to introduce the various Pax5 mutants into Pax5-/- B-cells. The
transduction experiments can be performed in vitro and the cells can then be evaluated
for evidence of differentiation by flow cytometry, Southern or PCR analysis for
immunoglobulin gene rearrangements, and bone marrow transplant assays for
differentiation and tumorigenic potential. The next logical progression of experiments
would be to generate knock-in animals expressing one or more of the Pax5 mutations.
By knocking in a Pax5 point mutation into the Pax5 locus we can ask several important
questions. First, is the mutation conducive to life, that is, does the presence of the
mutation cause the death of the animal? Second, what is the spectrum of B-cell
development within the bone marrow compartment of the animal? Are there any off-site
effects of the Pax5 mutation; does the mutation affect other tissues? A knock in animal
model will also be very important for future work because expression of the Pax5
mutation is controlled by the Pax5 locus and not a viral LTR which results in abnormally
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high expression of the associated gene. Thus, is Pax5 mutant expression at normal levels
that is sensitive to normal cellular signaling cues, sufficient for normal B-cell
development or is it insufficient or perhaps even oncogenic? This series of experiments
is critical because it is very possible that expression of hypomorphic allele at high levels
is enough to confer normal Pax5 effects, whereas, expression of the same hypomorphic
allele at normal physiologic levels may result in a block in B-cell development.
The generation of knock in animals that harbor Ikaros mutations will also be an
important series of experiments to perform. We have shown in chapter 4 that deletions of
the IKZF1 (Ikaros) gene are almost a required event in Ph+ leukemia. Not only do most
BCR-ABL1 leukemias harbor deletions of the Ikaros gene, but we have shown in a recent
study that deletion of Ikaros is a negative prognostic indicator in ALL.107 Because many
of the Ikaros deletions result in internally truncated mutants that are expected to behave
as dominant negative inhibitors of normal Ikaros function, it will be important to generate
an Ikaros mutant knock in animal model. Again, by knocking the mutant Ikaros allele
into the normal germline Ikaros locus we will be able to better appreciate the changes
associated with the mutant allele. We will ask questions like what are the consequences
of Ikaros mutant; how does it affect normal hematopoiesis? If the Ikaros mutants are in
fact dominant negative inhibitors of normal Ikaros function then we will be able to asses
those effects by performing DNA binding assays, transactivation assays, and Western
blot analyses to determine the effects that the mutant has alone and the effects that it has
on normal Ikaros function. Additional studies regarding the leukemogenic effects of the
Ikaros mutant knock-in, as well as, cooperation with BCR-ABL1 or other oncogenes will
be of great interest.
Importantly, many pediatric ALL cases harbor mutations of both PAX5 and Ikaros
suggesting that multiple lesions within the B-cell development and differentiation
pathway may cooperate during leukemogenesis. Once the generation of both the PAX5
and Ikaros knock-in animals is completed then these models can then be crossed and
analyzed for effects on the hematopoietic system. It will be important to assess the ability
of these mutations to cooperate to impair B-cell development both in the presence of an
oncogene like BCR-ABL1 and in the absence of any oncogene. The results of these
experiments will help in our understanding of exactly how the loss of PAX5 or Ikaros
really contributes to the development of ALL.
In chapter 3 we discussed some of the insights we have gained into how the loss
Pax5 may contribute to the development of ALL. We discussed the previous findings
that during normal B-cell development, as defined by Hardy fraction analysis, Pax5
expression in turned on in fraction B and remains expressed in mature circulating Blymphocytes. If one allele of Pax5 is lost then the gene expression profiles of all Hardy
fractions from B distally change. Even more impressive is the loss of both Pax5 alleles
which completely arrest B-cell development at Hardy fraction B. We have expanded the
previously published data on the transcriptional networks that function during B-cell
development. Our gene expression profiling of B-cell development has revealed a
significant increase in the number and scope of genes that are regulated by Pax5 as
defined by changes in the gene expression profiles of Pax5 haploinsufficient and null B-
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cells. Another important future experiment will be to elucidate which Pax5 responsive
genes are primary targets by performing ChIP-sequencing analysis. We have also shown
using principal component analysis and gene set enrichment analysis that Hardy fraction
B is enriched for a set of genes commonly expressed in embryonic stem cells. It is no
surprise then, that in pre-B leukemias, the stage of developmental arrest is Hardy fraction
B, where there is expression of a set of stem cell genes. The enrichment of this core
ESC-like geneset was also seen in our murine leukemias further supporting the link
between Hardy fraction B arrest and leukemogenic potential. I would speculate that the
loss of Pax5 in the context of BCR-ABL1 expression confers a block in B-cell
development sufficient to prevent the leukemia from differentiating beyond Hardy
fraction B and, as a result, arrests the leukemia at a stage of development that retains a
stem cell-like phenotype.
Interestingly, leukemias that started as Pax5+/- Arf+/- still retained expression of
the wild-type Arf allele at the protein level suggesting that the two pathways regulated by
Pax5 and Arf somehow cooperate during leukemogenesis. Arf has long been proposed to
be a prototypical two-hit tumor suppressor. And there is some evidence that suggests, in
the context of BCR-ABL1, that if one Arf allele is lost then both Arf alleles will be lost
during leukemogenesis75. Our data would suggest that in the context of Pax5
haploinsufficiency, Arf haploinsufficiency cooperates and the wild-type Arf allele is
intact suggesting that loss of both Arf alleles is not necessary unless Pax5 somehow
regulates the Arf locus. If Pax5 were found to regulate Arf expression then this would
explain a possible mechanism by which Pax5 haploinsufficiency cooperates with BCRABL1 during leukemogenesis; by acting as a function hit to the Arf/Mdm2/p53 tumor
suppressor pathway. Future studies aimed at elucidating the possible role that Pax5 has in
regulating the Arf/Mdm2/p53 pathway will provide much needed insight.
In order to elucidate the role that Pax5 haploinsufficiency plays in regulating the
Arf tumor suppressor pathway we will perform a series of in vitro studies aimed at
assessing Arf protein levels in BCR-ABL1 positive B-cells of varying Pax5 genotype.
Specifically, we will transduce total bone marrow from wild-type, Pax5+/-, Arf+/- animals
with ecotropic retrovirus harboring the BCR-ABL1 oncogene using the cationic polymer
polybrene. Transduced bone marrow cells will then be cultured for seven days during
which time BCR-ABL1 expressing B-cell cultures will develop. Upon maturation of the
B-cell cultures, five million cells will be harvested for western blot and quantitative RTPCR analysis. The relative level of Arf protein and Arf transcript will be assessed and
compared from wild-type and Pax5+/- cultures, allowing us to determine the effect that
hemizygous loss of Pax5 has on Arf expression at the transcript and protein level.
Should we find that Pax5 haploinsufficiency does affect the level of Arf
expression in vitro then further experiments will be performed in vivo. We will harvest Bcells from wild-type, Pax5+/-, Pax5-/-, Arf+/- and Pax5+/- Arf+/- animals and use protein and
RNA extracted from these cells in the same series of analyses in order to determine the
effects that Pax5 dose has on Arf expression. This series of experiments will allow us to
determine the effects that Pax5 has on Arf expression during normal development in the
absence of BCR-ABL1 signaling. Additionally, using a Pax5 antibody directed at the
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DNA binding domain, we will perform chromatin imunoprecipitation (ChIP) experiments
in order to determine whether the changes in Arf expression is due to direct Pax5 binding
to the Arf promoter or due to down-stream signaling effects. This series of experiments
will be performed by harvesting B-cells from wild-type, Pax5+/-, Pax5-/-, Arf+/- and Pax5+/Arf+/- animals and subjecting them to a cross-linking reagent in order to actively crosslink transcription factors like Pax5 to their DNA targets. Cross-linked cells are then
sonicated in order to shear the chromatin into smaller fragments and then the cross-links
are reversed, DNA is extracted, and quantitative genomic PCR is performed using assays
designed for the Arf promoter as well as a control assay designed for the known Pax5
targets CD19 and Blnk. Analysis of the relative enrichment of Arf promoter to either the
CD19 or Blnk promoters will allow us to determine if Pax5 directly binds to the Arf
promoter.
In summary, our work to elucidate cooperating oncogenic lesions in pediatric
ALL has been very fruitful. Further work validating that these secondary oncogenic
lesions cooperate has shown that the lesions we have identified are real cooperating
lesions. Future work aimed at describing the mechanism by which these lesions cooperate
will be of vital importance if we are to progress toward somehow targeting these
dysregulated pathways therapeutically in an effort to bring Danny Thomas’ profound
mission statement to pass “That no child should die in the dawn of life”.
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